文献 | がん診療ガイドライン

文献

1）: Kudo S: Endoscopic mucosal resection of flat and depressed early colorectal cancer. Endoscopy 1993; 25: 455‒461
2）: 井上晴洋，竹下公矢，遠藤光夫，他: 早期胃癌に対する内視鏡的粘膜切除術―透明プラスチックキャップを用いる方法（EMRC）―．Gastroenterol Endosc 1993; 35: 600‒607
3）: Tanaka S, Oka S, Chayama K: Colorectal endoscopic submucosal dissection（ESD）: the present status and future perspective including its differentiation from endoscopic mucosal resection（EMR）. J Gastroenterol 2008; 43: 641‒651
4）: Tanaka S, Kashida H, Saito Y, et al: JGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig Endosc 2015; 27: 417‒434
5）: 田中信治，樫田博史，斎藤　豊，他: 大腸ESD/EMR ガイドライン．Gastroenterol Endosc 2014; 56: 1598‒1617
6）: Iwatate M, Sano Y, Tanaka S, et al: Validation study for development of the Japan NBI Expert Team classification of colorectal lesions Dig Endosc 2018; 30: 642‒651
7）: Saitoh Y, Obara T, Watari J, et al: Invasion depth diagnosis of depressed type early colorectal cancers by combined use of videoendoscopy and chromoendoscopy. Gastrointest Endosc 1998; 48: 362‒370
8）: Watari J, Saitoh Y, Obara T, et al: Early nonpolypoid colorectal cancer: radiographic diagnosis of depth of invasion. Radiology 1997; 205: 67‒74
9）: Tanaka S, Kaltenbach T, Chayama K, et al: High-magnification colonoscopy. Gastrointest Endosc 2006; 64: 604‒613
10）: 浜本順博，平田一郎，安本真悟，他: 早期大腸癌における浸潤度の臨床診断精度―超音波内視鏡を中心に．胃と腸2004; 39: 1375‒1386
11）: 若村邦彦，工藤進英，竹村織江，他: 大腸腺腫・早期癌の内視鏡切除後のfollow up．胃と腸2007; 42: 1453‒1457
12）: 浦上尚之，五十嵐正広，千野晶子，他: 大腸SM 癌の内視鏡切除後のfollow up―サーベイランスに向けて（局所再発，転移再発）．胃と腸2007; 42: 1470‒1476
13）: Oka S, Tanaka S, Kanao H, et al: Mid-term prognosis after endoscopic resection for submucosal colorectal carcinoma: summary of a multicenter questionnaire survey conducted by the colorectal endoscopic resection standardization implementation working group in Japanese Society for Cancer of the Colon and Rectum. Dig Endosc 2011; 23: 190‒194
14）: Kotake K, Mizuguchi T, Moritani K, et al: Impact of D3 lymph node dissection on survival for patients with T3 and T4 colon cancer. Int J Colorectal Dis 2014; 29: 847‒852
15）: Japanese Society for Cancer of the Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan, Cases treated in 2000‒2002. Vol. 29（2011）, Cases treated in 2003‒2004. Vol. 30（2012）
16）: Kotake K, Kobayashi H, Asano M, et al: Influence of extent of lymph node dissection on survival for patients with pT2 colon cancer. Int J Colorectal Dis 2015; 30: 813‒820
17）: Heald RJ, Husband EM, Ryall RD: The mesorectum in rectal cancer surgery―the clue to pelvic recurrence? Br J Surg 1982; 69: 613‒616
18）: MacFarlane JK, Ryall RD, Heald RJ: Mesorectal excision for rectal cancer. Lancet 1993; 341: 457‒460
19）: Enker WE, Thaler HT, Cranor ML, et al: Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181: 335‒346
20）: Lowry AC, Simmang CL, Boulos P, et al: Consensus statement of definitions for anorectal physiology and rectal cancer. Dis Colon Rectum 2001; 44: 915‒919
21）: Sugihara K, Kobayashi H, Kato T, et al: Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 2006; 49: 1663‒1672
22）: Hida J, Yasutomi M, Maruyama T, et al: The extent of lymph node dissection for colon carcinoma: the potential impact on laparoscopic surgery. Cancer 1997; 80: 188‒192
23）: Ono C, Yoshinaga K, Enomoto M, et al: Discontinuous rectal cancer spread in the mesorectum and the optimal distal clearance margin in situ. Dis Colon Rectum 2002; 45: 744‒749
24）: Shimada Y, Takii Y, Murayama S, et al: Intramural and mesorectal distal spread detected by whole-mount sections in the determination of optimal distal resection margin in patients undergoing surgery for rectosigmoid or rectal cancer without preoperative therapy. Dis Colon Rectum 2011; 54: 1510‒1520
25）: Shirouzu K, Isomoto H, Kakegawa T: Distal spread of rectal cancer and optimal distal margin of resection for sphincter-preserving surgery. Cancer 1995; 76: 388‒392
26）: Zhao GP, Zhou ZG, Lei WZ, et al: Pathological study of distal mesorectal cancer spread to determine a proper distal resection margin. World J Gastroenterol 2005; 11: 319‒322
27）: Martin ST, Heneghan HM, Winter DC: Systematic review of outcomes after intersphincteric resection for low rectal cancer. Br J Surg 2012; 99: 603‒612
28）: 山田一隆，緒方俊二，佐伯泰愼，他:［第 84 回大腸癌研究会アンケート調査報告］括約筋間直腸切除術（ISR）の適応と長期成績．大腸疾患NOW2017‒2018，日本メディカルセンター，東京，2017; 125‒130
29）: 山田一隆，緒方俊二，佐伯泰愼，他: 下部直腸・肛門管癌に対する括約筋間直腸切除術（ISR）の術後排便機能障害．日本大腸肛門病会誌2016; 69: 513‒520
30）: Pollack J, Holm T, Cedermark B, et al: Long-term effect of preoperative radiation therapy on anorectal function. Dis Colon Rectum 2006; 49: 345‒352
31）: Lange MM, den Dulk M, Bossema ER, et al; Cooperative Clinical Investigators of the Dutch Total Mesorectal Excision Trial: risk factors for faecal incontinence after rectal cancer treatment. Br J Surg 2007; 94: 1278‒1284
32）: Yamada K, Ogata S, Saiki Y, et al: Long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum 2009; 52: 1065‒1071
33）: Fujita S, Akasu T, Mizusawa J, et al; Colorectal Cancer Study Group of Japan Clinical Oncology Group: Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage Ⅱ or stage Ⅲ lower rectal cancer（JCOG0212）: results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol 2012; 13: 616‒621
34）: Saito S, Fujita S, Mizusawa J, et al; Colorectal Cancer Study Group of Japan Clinical Oncology Group: Male sexual dysfunction after rectal cancer surgery: Results of a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for patients with lower rectal cancer: Japan Clinical Oncology Group Study JCOG0212. Eur J Surg Oncol 2016; 42: 1851‒1858
35）: Ito M, Kobayashi A, Fujita S, et al; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Urinary dysfunction after rectal cancer surgery: Results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage Ⅱ or Ⅲ lower rectal cancer（Japan Clinical Oncology Group Study, JCOG0212）. Eur J Surg Oncol 2018; 44: 463‒468
36）: 大腸癌研究会: 大腸癌取扱い規約，第9 版，東京，金原出版; 2018
37）: Mentges B, Buess G, Schäfer D, et al: Local therapy of rectal tumors. Dis Colon Rectum 1996; 39: 886‒892
38）: Maeda K, Maruta M, Sato H, et al: Outcomes of novel transanal operation for selected tumors in the rectum. J Am Coll Surg 2004; 199: 353‒360
39）: Santibanes E, Lassalle FB, McCormack L, et al: Simultaneous colorectal and hepatic resections for colorectal cancer: Postoperative and longterm outcomes. J Am Coll Surg 2002; 195: 196‒202
40）: 望月英隆: 腹膜播種を伴う大腸癌．上西紀夫，田中雅夫（編），消化器癌の外科治療，東京，中外医学社; 2001: 100‒102
41）: 岡　正朗，内山哲史，森近博史，他: 腹膜播種を伴う大腸癌症例の臨床病理学的検討―肝転移例との比較―．日臨外医会誌1993; 54: 2535‒2539
42）: 正木忠彦，武藤徹一郎，安富正幸: 大動脈周囲リンパ節の実態―第44 回大腸癌研究会アンケート調査報告．日本大腸肛門病会誌1997; 50: 318‒330
43）: Nakai N, Yamaguchi T, Kinugasa Y, et al: Long-term outcomes after resection of para-aortic lymph node metastasis from left-sided colon and rectal cancer. Int J Colorectal Dis 2017; 32: 999‒1007
44）: Min BS, Kim JS, Kim NK, et al: Extended lymph node dissection for rectal cancer with radiologically diagnosed extramesenteric lymph node metastasis. Ann Surg Oncol 2009; 16: 3271‒3278
45）: Choi PW, Kim HC, Kim AY, et al: Extensive lymphadenectomy in colorectal cancer with isolated para-aortic lymph node metastasis below the level of renal vessels. J Surg Oncol 2010; 101: 66‒71
46）: Arimoto A, Uehara K, Kato T, et al: clinical significance of para-aortic lymph node dissection for advanced or metastatic colorectal cancer in the current era of modern chemotherapy. Dig Surg 2015; 32: 439‒444
47）: Bae SU, Han YD, Cho MS, et al: Oncologic outcomes of colon cancer patients with extraregional lymph node metastasis: comparison of isolated paraaortic lymph node metastasis with resectable liver metastasis. Ann Surg Oncol 2016; 23: 1562‒1568
48）: Murata S, Moriya Y, Akasu T, et al: Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998; 83: 1086‒1093
49）: Kobayashi K, Kawamura M, Ishihara T: Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 1999; 118: 1090‒1096
50）: Robinson BJ, Rice TW, Strong SA, et al: Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 1999; 117: 66‒76
51）: 森谷冝皓，山口高史，赤須孝之，他: 骨盤内局所再発癌に対する積極的外科治療．臨外2001; 56: 759‒765
52）: Lambert LA, Colacchio TA, Barth RJ Jr: Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 2000; 135: 473‒479
53）: Yoshidome H, Kimura F, Shimizu H, et al: Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases? J Gastrointest Surg 2008; 12: 1391‒1398
54）: Adam R: Developing strategies for liver metastases from colorectal cancer. Semin Oncol 2007; 34（2 Suppl 1）: S7‒11
55）: Lam VW, Spiro C, Laurence JM, et al: A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 2012; 19: 1292‒1301
56）: Min BS, Kim NK, Sohn SK, et al: Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma. J Surg Oncol 2008; 97: 136‒140
57）: Wong JS, Tan GH, Teo MC. Management of para-aortic lymph node metastasis in colorectal patients: A systemic review. Surg Oncol 2016; 25: 411‒418
58）: Nagata H, Ishihara S, Hata K, et al: Survival and prognostic factors for metachronous peritoneal metastasis in patients with colon cancer. Ann Surg Oncol. 2017; 24: 1269‒1280
59）: Franzese C, Fogliata A, Comito T, et al: Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. Br J Radiol 2017; 90: 20170422
60）: Isozaki Y, Yamada S, Kawashiro S, et al: Carbon-ion radiotherapy for isolated para-aortic lymph node recurrence from colorectal cancer. J Surg Oncol 2017; 116: 932‒938
61）: Kim MS, Cho CK, Yang KM, et al: Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. World J Gastroenterol 2009; 15: 6091‒6095
62）: Tschmelitsch J, Kronberger P, Glaser K, et al: Survival after surgical treatment of recurrent carcinoma of the rectum. J Am Coll Surg 1994; 179: 54‒58
63）: Tanis PJ, Doeksen A, van Lanschot JJ: Intentionally curative treatment of locally recurrent rectal cancer: a systematic review. Can J Surg 2013; 56: 135‒144
64）: Martin LW, Warren RS: Current management of colorectal liver metastases. Surg Oncol Clin N Am 2000; 9: 853‒876
65）: Penna C, Nordlinger B: Colorectal metastasis（liver and lung）. Surg Clin North Am 2002; 82: 1075‒1090
66）: Abdalla EK, Vauthey JN, Ellis LM, et al: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818‒825; discussion 825‒827
67）: Nordlinger B, Sorbye H, Glimelius B, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und‒tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie（ALM‒CAO）; Australasian Gastro-Intestinal Trials Group（AGITG）; Fédération Francophone de Cancérologie Digestive（FFCD）: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer（EORTC 40983）: long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208‒1215
68）: Kato T, Yasui K, Hirai T, et al: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy. Dis Colon Rectum 2003; 46（Suppl）: S22‒S31
69）: Niekel MC, Bipat S, Stoker J: Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257: 674‒684
70）: Moulton CA, Gu CS, Law CH, et al: Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA 2014; 311: 1863‒1869
71）: Fortner JG, Silva JS, Golbey RB, et al: Multivariate analysis of hepatic metastases from colorectal cancer. Ⅰ. Treatment by hepatic resection. Ann Surg 1984; 199: 306‒316
72）: Hughes KS, Simon R, Songhorabodi S, et al: Resection of the liver for colorectal carcinoma metastases: a multiinstitutional study of pattern of recurrence. Surgery 1986; 100: 278‒284
73）: Ekberg H, Tranberg KG, Andersson R, et al: Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987; 11: 541‒547
74）: Battula N, Tsapralis D, Mayer D, et al: Repeat liver resection for recurrent colorectal metastases: a single-centre, 13-year experience. HPB（Oxford）2014; 16: 157‒163
75）: Nordinger B, Jaeck D, Guiguet M, et al: Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery. In: Nordinger B, Jaeck D, editors, Treatment of hepatic metastases of colorectal cancer. Paris Springer-Verlag 1992: 129‒146
76）: Cady B, Jenkins RL, Steele Jr GD, et al: Surgical margin in hepatic resection for colorectal metastases: a critical and improvable determinant of outcome. Ann Surg 1998; 227: 566‒571
77）: Yamamoto J, Sugihara K, Kosuge T, et al: Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. Ann Surg 1995; 221: 74‒78
78）: Elias D, Cavalcanti A, Sabourin JC, et al: Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998; 69: 88‒93
79）: Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938‒946
80）: Kokudo N, Miki Y, Sugai S, et al: Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002; 137: 833‒840
81）: Bismuth H, Castaing D, Traynor O: Surgery for synchronous hepatic metastases of colorectal cancer. Scand J Gastroenterol Suppl 1988; 149: 144‒149
82）: Scheele J: Hepatectomy for liver metastases. Br J Surg 1993; 80: 274‒276
83）: Adam R, de Gramont A, Figueras J, et al; of the EGOSLIM（Expert Group on OncoSurgery management of LIver Metastases）group: Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 2015; 41: 729‒741
84）: Rodgers MS, McCall JL: Surgery for colorectal liver metastases with hepatic lymph-node involvement: a systematic review. Br J Surg 2000; 87: 1142‒1155
85）: Beckurts KT, Hölscher AH, Thorban ST, et al: Significance of lymph node imvolvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg 1997; 84: 1081‒1084
86）: Nakamura S, Suzuki S, Konno H: Resection of hepatic metastases of colorectal carcinoma: 20 years’ experience. J Hepatobiliary Pancreat Surg 1999; 6: 16‒22
87）: Regnard JF, Grunenwald D, Spaggiari L, et al: Surgical treatment for hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998; 66: 214‒218
88）: Carpizo DR, Are C, Jarnagin W, et al: Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol 2009; 16: 2138‒2146
89）: Chua TC, Saxena A, Liauw W, et al: Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases‒‒a systematic review. Eur J Cancer 2012; 48: 1757‒1765
90）: Nordlinger B, Vaillant JC, Guiguet M, et al: Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12: 1491‒1496
91）: Yamamoto J, Kosuge T, Shimada K, et al: Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 1999; 178: 275‒281
92）: Petrowsky H, Gonen M, Jarnagin W, et al: Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235: 863‒871
93）: Suzuki S, Sakaguchi T, Yokoi Y, et al: Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 2001; 129: 421‒428
94）: Nagakura S, Shirai Y, Suda T, et al: Multiple repeat resections of intra- and extrahepatic recurrences in patients undergoing initial hepatectomy for colorectal carcinoma metastases. World J Surg 2002; 26: 141‒147
95）: Tanaka K, Shimada H, Ohta M, et al: Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer. World J Surg 2004; 28: 482‒487
96）: Thelen A, Jonas S, Benckert C, et al: Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol 2007; 33: 324‒328
97）: Pessaux P, Lermite E, Brehant O, et al: Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006; 93: 1‒7
98）: Ishiguro S, Akasu T, Fujimoto Y, et al: Second hepatectomy for recurrent colorectal liver metastasis: analysis of preoperative prognostic factors. Ann Surg Oncol 2006; 13: 1579‒1587
99）: Tree AC, Khoo VS, Eeles RA, et al: Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013; 14: e28‒37
100）: Goya T, Miyazawa N, Kondo H, et al: Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 1989; 64: 1418‒1421
101）: McCormack PM, Burt ME, Bains MS, et al: Lung resection of colorectal metastases. 10-year results. Arch Surg 1992; 127: 1403‒1406
102）: Ike H, Shimada H, Ohki S, et al: Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum 2002; 45: 468‒475
103）: Okumura S, Kondo H, Tsuboi M, et al: Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996; 112: 867‒874
104）: McAfee MK, Allen MS, Trastek VF, et al: Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992; 53: 780‒785
105）: 緒方　裕，的野敬子，林　明宏，他: 大腸癌肺転移に対する肺切除の遠隔成績．日臨外会誌2001; 62: 2110‒2115
106）: 丸田智章，須田武保，畠山勝義，他: 大腸癌肺転移に対する肺切除の検討．日消外会誌2002; 35: 1377‒1383
107）: Saito Y, Omiya H, Kohno K, et al: Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124: 1007‒1013
108）: 金光幸秀，加藤知行，平井　孝: 大腸癌肺転移に対する治療の現況―第55 回大腸癌研究会アンケート結果―．日本大腸肛門病会誌2004; 57: 121‒131
109）: 斎藤　裕，高田宗尚，矢鋪憲功，他: 大腸癌肺転移の手術成績からみた手術適応．北陸外科学会雑誌2005; 24: 5‒8
110）: 東山聖彦，高見康二，檜垣直純，他: 大腸癌肺転移に対する外科治療―手術適応，工夫と成績について―．臨床消化器内科2005; 20: 199‒206
111）: Koga R, Yamamoto J, Saiura A, et al: Surgical resection of pulmonary metastases from colorectal cancer: four favourable prognostic factors. Jpn J Clin Oncol 2006; 36: 643‒648
112）: Iizasa T, Suzuki M, Yoshida S, et al: Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006; 82: 254‒260
113）: Watanabe K, Nagai K, Kobayashi A, et al: Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 2009; 96: 1058‒1065
114）: Iida T, Nomori H, Shiba M, et al; Metastatic Lung Tumor Study Group of Japan. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg 2013; 257: 1059‒1064
115）: Kanemitsu Y, Kato T, Hirai T, et al: Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004; 91: 112‒120
116）: Hirosawa T, Itabashi M, Ohnuki T, et al; Japanese Society for Cancer of the Colon and Rectum（JSCCR）Study Group for Pulmonary Metastases from Colorectal Cancer: Prognostic factors in patients undergoing complete resection of pulmonary metastases of colorectal cancer: a multi-institutional cumulative follow-up study. Surg Today 2013; 43: 494‒499
117）: Gonzalez M, Poncet A, Combescure C, et al: Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2013; 20: 572‒579
118）: Miller G, Biernacki P, Kemeny NE, et al: Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2007; 205: 231‒238
119）: Andres A, Mentha G, Adam R, et al: Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases. Br J Surg 2015; 102: 691‒699
120）: Kandioler D, Krömer E, Tüchler H, et al: Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg 1998; 65: 909‒912
121）: Kanzaki R, Higashiyama M, Oda K, et al: Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. Am J Surg 2011; 202: 419‒426
122）: Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494‒500
123）: Go PH, Klaassen Z, Meadows MC, et al: Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 2011; 117: 3630‒3640
124）: Wronski M, Arbit E: Resection of brain metastases from colorectal carcinoma in 73 patients. Cancer 1999; 85: 1677‒1685
125）: D ’Andrea G, Isidori A, Caroli E, et al: Single cerebral metastasis from colorectal adenocarcinoma. Neurosurg Rev 2004; 27: 55‒57
126）: Farnell GF, Buckner JC, Cascino T: Brain metastases from colorectal carcinoma. Cancer 1996; 78: 711‒716
127）: Jung M, Ahn JB, Chang JH, et al: Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol 2011; 101: 49‒55
128）: Aprile G, Zanon E, Tuniz F, et al: Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J Cancer Res Clin Oncol 2009; 135: 451‒457
129）: Noura S, Ohue M, Shingai T, et al: Brain metastasis from colorectal cancer: prognostic factors and survival. J Surg Oncol 2012; 106: 144‒148
130）: Borgelt B, Gelber R, Kramer S, et al: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6: 1‒9
131）: Kurtz JM, Gelber R, Brady LW, et al: The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981; 7: 891‒895
132）: Flickinger JC, Kondziolka D, Lunsford LD, et al: A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 1994; 28: 797‒802
133）: Silva IL, Iskandarani M, Hotouras A, et al: A systematic review to assess the management of patients with cerebral metastases secondary to colorectal cancer. Tech Coloproctol 2017; 21: 847‒852
134）: Gasper L, ScottC, Rotman M, et al: Recursive partitioning analysis（RPA）of prognostic factors in three Radiation Therapy Oncology Group（RTOG）brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745‒751
135）: van Gijn W, Marijnen CA, Nagtegaal ID, et al: Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575‒582
136）: Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30: 419‒425
137）: Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665‒1672
138）: Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole-brain radiotherapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295: 2483‒2491
139）: André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer（MOSAIC）Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343‒2351
140）: Haller DG, Tabernero J, Maroun J, et al: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage Ⅲ colon cancer. J Clin Oncol 2011; 29: 1465‒1471
141）: Shimada Y, Hamaguchi T, Mizusawa J, et al: Randomised phase Ⅲ trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage Ⅲ colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer 2014; 50: 2231‒2240
142）: Yoshida M, Ishiguro M, Ikejiri K, et al: S-1 as adjuvant chemotherapy for stage Ⅲ colon cancer: a randomized phase Ⅲ study（ACTS‒CC trial）. An Oncol 2014; 25: 1743‒1749
143）: Hamaguchi T, Shimada Y, Mizusawa J, et al: Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage Ⅲ colorectal cancer（JCOG0910）: an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 2018; 3: 47‒56
144）: Grothey A, Sobrero AF, Shields AF, et al: Duration of adjuvant chemotherapy for stage Ⅲ colon cancer. N Engl J Med 2018; 378: 1177‒1188
145）: Yoshino T, Yamanaka T, Kotaka D, et al: Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage Ⅲ colon cancer（CC）: Results from phase Ⅲ ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy（IDEA）Collaboration. An Oncol 2017; 28: mdx440.017
146）: Kotaka M, Yamanaka T, Yoshino T, et al: Safety data from the phase Ⅲ Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase Ⅲ trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage Ⅲ colon cancer. ESMO Open 2018; 3: e000354
147）: Sadahiro S, Tsuchiya T, Sasaki K, et al: Randomized phase Ⅲ trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage ⅡB/Ⅲ colon cancer: final results of JFMC33‒0502. Ann Oncol 2015; 26: 2274‒2280
148）: Yamaguchi S, Kunieda K, Sato T, et al: Phase Ⅲ trial of 24 weeks vs. 48 weeks capecitabine adjuvant chemotherapy for patients with stage Ⅲ colon cancer: Final results of JFMC37‒0801. Ann Oncol 2016; 27: suppl_6, 469PD
149）: Sakamoto J, Hamada C, Yoshida S, et al: An individual patient data meta-analysis of adjuvant therapy with uracil‒tegafur（UFT）in patients with curatively resected rectal cancer. Br J Cancer 2007; 96: 1170‒1177
150）: Oki E, Murata A, Yoshida K, et al: A randomized phase Ⅲ trial comparing S-1 versus UFT as adjuvant chemotherapy for stage Ⅱ/Ⅲ rectal cancer（JFMC35‒C1: ACTS‒RC）. Ann Oncol 2016; 27: 1266‒1272
151）: Matsuda C, Ishiguro M, Teramukai S, et al; SACURA Study Group. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur‒uracil versus surgery alone in stage Ⅱ colon cancer: SACURA trial. Eur J Cancer. 2018; 96: 54‒63
152）: Hasegawa K, Saiura A, Takayama T, et al: Adjuvant oral uracil‒tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS One 2016; 11: e0162400
153）: Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321: 531‒535
154）: Yamada Y, Takahari D, Matsumoto H, et al: Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer（SOFT）: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 2013; 14: 1278‒1286
155）: Loupakis F, Cremolini C, Masi G, et al: Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609‒1618
156）: Yamazaki K, Nagase M, Tamagawa H, et al: Randomized phase Ⅲ study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer（WJOG4407G）. Ann Oncol 2016; 27: 1539‒1546
157）: Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413‒1418
158）: Taniguchi H, Yamazaki K, Yoshino T, et al: Japanese Society of Medical Oncology Clinical Guidelines: RAS（KRAS/NRAS）mutation testing in colorectal cancer patients. Cancer Sci 2015; 106: 324‒327
159）: de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938‒2947
160）: Goldberg R, Sargent D, Morton R, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23‒30
161）: Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase Ⅲ study. J Clin Oncol 2008; 26: 2013‒2019
162）: Cassidy J, Clarke S, Díaz-Rubio E, et al: Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006‒2012
163）: Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229‒237
164）: Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041‒1047
165）: Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC‒C Study. J Clin Oncol 2007; 25: 4779‒4786
166）: Yamada Y, Denda T, Gamoh M, et al: S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer（TRICOLORE）: a randomized, open-label, phase Ⅲ, noninferiority trial. Ann Oncol 2018; 29: 624‒631
167）: Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663‒671
168）: Douillard JY, Siena S, Cassidy J, et al: Randomized, phase Ⅲ trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin（FOLFOX4）versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697‒4705
169）: Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408‒1417
170）: Köhne CH, Hofheinz R, Mineur L, et al: First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2012; 138: 65‒72
171）: Falcone A, Ricci S, Brunetti I, et al: Gruppo Oncologico Nord Ovest: Phase Ⅲ trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan（FOLFOXIRI）compared with infusional fluorouracil, leucovorin, and irinotecan（FOLFIRI）as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670‒1676
172）: Cremolini C, Loupakis F, Antoniotti C, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306‒1315
173）: Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559‒1565
174）: de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808‒815
175）: Hurwitz H, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502‒3508
176）: Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase Ⅱ, randomized trial comparing Bevacizumab plus fluorouracil（FU）/leucovorin（LV）with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60‒65
177）: Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase Ⅲ study. J Clin Oncol 2001; 19: 2282‒2292
178）: Van Cutsem E, Twelves C, Cassidy J, et al: Xeloda Colorectal Cancer Study Group: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase Ⅲ study. J Clin Oncol 2001; 19: 4097‒4106
179）: Tebbutt NC, Wilson K, Gebski VJ, et al: Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase Ⅲ MAX Study. J Clin Oncol 2010; 28: 3191‒3198
180）: Shirao K, Hoff PM, Ohtsu A, et al: Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur（UFT）plus oral leucovorin（LV）regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 2004; 22: 3466‒3474
181）: Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phase Ⅲ study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605‒3616
182）: Carmichael J, Popiela T, Radstone D, et al: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3617‒3627
183）: Nishina T, Moriwaki T, Shimada M, et al: Uracil‒tegafur and oral leucovorin combined with bevacizumab in elderly patients（aged≥75 years）with metastatic colorectal cancer: a multicenter, phase Ⅱ trial（joint study of bevacizumab, oral leucovorin, and uracil‒tegafur in elderly patients［J‒BLUE］study）. Clin Colorectal Cancer 2016; 15: 236‒242
184）: Yoshida M, Muro K, Tsuji A, et al: Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer（BASIC trial）. Eur J Cancer 2015; 51: 935‒941
185）: Pierantonio F, Cremolini C, Aprile G, et al: Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: challenging drug label to light up new hope. Onoclogist 2015; 20: 1261‒1265
186）: Sastre J, Massuti B, Pulido G, et al: First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase Ⅱ study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer 2015; 51: 1371‒1380
187）: Bennouna J, Sastre J, Arnold D, et al: ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer（ML18147）: a randomised phase 3 trial. Lancet Oncol 2013; 14: 29‒37
188）: Iwamoto S, Takahashi T, Tamagawa H, et al: FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase Ⅲ EAGLE study. Ann Oncol 2015; 26: 1427‒1433
189）: Xu RH, Muro K, Morita S, et al: Modified XELIRI（capecitabine plus irinotecan）versus FOLFIRI（leucovorin, fluorouracil, and irinotecan）, both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer（AXEPT）: a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660‒671
190）: Tabernero J, Yoshino T, Cohn AL, et al: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine（RAISE）: a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16: 499‒508
191）: Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase Ⅲ randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499‒3506. Epub 2012 Sep 4
192）: Muro K, Boku N, Shimada Y, et al: Irinotecan plus S-1（IRIS）versus fluorouracil and folinic acid plus irinotecan（FOLFIRI）as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study（FIRIS study）. Lancet Oncol 2010; 11: 853‒860
193）: Rougier P, Van Custem E, Bajetta E et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407‒1412
194）: Kuramochi H, Ando M, Itabashi M, et al: Phase Ⅱ study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. Cancer Chemother Pharmacol 2017; 79: 579‒585
195）: Peeters M, Price TJ, Cervantes A, et al: Randomized phase Ⅲ study of panitumumab with fluorouracil, leucovorin, and irinotecan（FOLFIRI）compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706‒4713
196）: Shitara K, Yonesaka K, Denda T, et al: Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer‒WJOG 6210 G. Cancer Sci 2016; 107: 1843‒1850
197）: Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: phase Ⅲ trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311‒2319
198）: Seymour MT, Brown SR, Middleton G, et al: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer（PICCOLO）: a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749‒759
199）: Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509‒2520
200）: Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil‒leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil‒leucovorin: interim results of a phase Ⅲ trial. J Clin Oncol 2003; 21: 2059‒2069
201）: Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin（FOLFOX4）for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539‒1544
202）: Rothenberg ML, Cox JV, Butts C, et al: Capecitabine plus oxaliplatin（XELOX）versus 5-fluorouracil/folinic acid plus oxaliplatin（FOLFOX-4）as second-line therapy in metastatic colorectal cancer: a randomized phase Ⅲ non-inferiority study. Ann Oncol 2008; 19: 1720‒1726
203）: Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337‒345
204）: Jonker DJ, O’Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040‒2048
205）: Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757‒1765
206）: Van Cutsem E, Peeters M, Siena S, et al: Open-label phase Ⅲ trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658‒1664
207）: Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626‒1634
208）: Grothey A, Van Cutsem E, Sobrero A, et al: CORRECT Study Group: Regorafenib monotherapy for previously treated metastatic colorectal cancer（CORRECT）: an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303‒312
209）: Yoshino T, Mizunuma N, Yamazaki K, et al: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012; 13: 993‒1001
210）: Mayer RJ, Van Cutsem E, Falcone A, et al: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372: 1909‒1919
211）: Xu J, Kim TW, Shen L, et al: Results of a randomized, double-blind, placebo-controlled, phase Ⅲ trial of trifluridine/tipiracil（TAS-102）monotherapy in Asian patients with previously treated metastatic colorectal cancer: The TERRA study. J Clin Oncol 2018; 36: 350‒358
212）: Satoh T, Ura T, Yamada Y, et al: Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1^＊28 and/or UGT1A1^＊6 polymorphisms. Cancer Sci 2011; 102: 1868‒1873
213）: Oki E, Kato T, Bando H, et al: A multicenter clinical phase Ⅱ study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study. Clin Colorectal Cancer 2018; 17: 147‒155
214）: Meta-Analysis Group in Cancer, Piedbois P, Buyse M, et al: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252‒258
215）: Yoshino T, Arnold D, Taniguchi H, et al: Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO‒ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 2018; 29: 44‒70
216）: Yamazaki K, Taniguchi H, Yoshino T, et al: Japanese Society of Medical Oncology Clinical Guidelines: Molecular testing for colorectal cancer treatment, third edition. Cancer Sci 2018; 109: 2074‒2079
217）: Arnold D, Lueza B, Douillard JY, et al: Prognostic and predictive value of primary tumour side in patients with RAS wild‒type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017; 28: 1713‒1729
218）: Yokota T, Ura T, Shibata N, et al: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104: 856‒862
219）: Kawazoe A, Shitara K, Fukuoka S, et al: A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer 2015; 15: 258
220）: Loupakis F, Cremolini C, Salvatore L, et al: FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014; 50: 57‒63
221）: 日本臨床腫瘍学会編: 大腸がん診療における遺伝子関連検査のガイダンス　第3 版，金原出版，東京，2016
222）: van Geel RMJM, Tabernero J, Elez E, et al: A Phase Ⅰb dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov 2017; 7: 610‒619
223）: Corcoran RB, André T, Atreya CE, et al: Combined BRAF, EGFR, and MEK inhibition in patients with BRAF^V600E-mutant colorectal cancer. Cancer Discov 2018; 8: 428‒443
224）: Venderbosch S, Nagtegaal ID, Maughan TS, et al: Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20: 5322‒5330
225）: Overman MJ, McDermott R, Leach JL, et al: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer（CheckMate 142）: an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18: 1182‒1191
226）: 大腸癌研究会編: 遺伝性大腸癌診療ガイドライン2016 年版，金原出版，東京，2016
227）: Ishida H, Yamaguchi T, Tanakaya K, et al: Japanese Society for Cancer of the Colon and Rectum（JSCCR）Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer（Translated Version）. J Anus Rctum Colon 2018; 2: 1‒51
228）: 日本臨床腫瘍学会・日本癌治療学会・日本癌学会　合同．1）次世代シークエンサー等を用いた遺伝子パネル検査に基づくがん診療ガイドライン（第1.0 版）（2017 年10 月11 日）https://www.jca.gr.jp/researcher/topics/2017/files/20171013.pdf
229）: Merker JD, Oxnard GR, Compton C, et al: Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018; 36: 1631‒1641
230）: Skibber JM, Hoff PM, Minsky BD, et al: Cancer of the rectum. In: Devita VT, Hellman S, Rosenberg SA（eds）. Cancer: principles and practice of oncology（6th ed）. Philadelphia, Lippincott, Williams and Wilkins 2001; 1271‒1318
231）: Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980‒987
232）: Camma C, Giunta M, Fiorica F, et al: Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. J Am Med Assoc 2000; 284: 1008‒1015
233）: Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 2001; 358: 1291‒1304
234）: Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638‒646
235）: Peeters KC, Marijnen CA, Nagtegaal ID, et al; Dutch Colorectal Cancer Group: The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693‒701
236）: Marijnen CA, van de Velde CJ, Putter H, et al: Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23: 1847‒1858
237）: Peeters KC, van de Velde CJ, Leer JW, et al: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients―a Dutch colorectal cancer group study. J Clin Oncol 2005; 23: 6199‒6206
238）: Francois Y, Nemoz CJ, Baulieux J, et al: Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90‒01 randomized trial. J Clin Oncol 1999; 17: 2396‒2402
239）: Bosset JF, Collette L, Calais G, et al: EORTC Radiotherapy Group Trial 22921: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114‒1123
240）: Gérard JP, Conroy T, Bonnetain F, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3‒4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620‒4625
241）: Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215‒1223
242）: Ngan SY, Burmeister B, Fisher RJ, et al: Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30: 3827‒3833
243）: Sauer R, Becker H, Hohenberger W, et al; German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731‒1740
244）: Hofheinz RD, Wenz F, Post S, et al: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13: 579‒588
245）: Allegra CJ, Yothers G, O’Connell MJ, et al: Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A phase Ⅲ randomized clinical trial. J Natl Cancer Inst 2015; 107: pii djv248
246）: Aschele C, Cionini L, Lonardi S, et al: Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR‒01 randomized phase Ⅲ trial. J Clin Oncol 2011; 29: 2773‒2780
247）: Gérard JP, Azria D, Gourgou-Bourgade S, et al: Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase Ⅲ trial ACCORD 12/0405‒Prodige 2. J Clin Oncol 2010; 28: 1638‒1644
248）: Gérard JP, Azria D, Gourgou-Bourgade S, et al: Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30: 4558‒4565
249）: Rödel C, Graeven U, Fietkau R, et al; German Rectal Cancer Study Group: Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer（the German CAO/ARO/AIO‒04 study）: final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015; 16: 979‒989
250）: Wolmark N, Wieand HS, Hyams DM, et al: Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project protocol R‒02. J Natl Cancer Inst 2000; 92: 388‒396
251）: Gervaz PA, Wexner SD, Pemberton JH: Pelvic radiation and anorectal function: introducing the concept of sphincter-preserving radiation therapy. J Am Coll Surg 2002; 195: 387‒394
252）: Temple LK, Wong WD, Minsky B: The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation. Semin Radiat Oncol 2003; 13: 469‒477
253）: Hong TS, Moughan J, Garofalo MC, et al: NRG Oncology Radiation Therapy Oncology Group 0822: A phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015; 93: 29‒36
254）: National Institute of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444‒1450
255）: O ’Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502‒507
256）: Smalley SR, Benedetti JK, Williamson SK, et al: Phase Ⅲ trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006; 24: 3542‒3547
257）: Nakfoor BM, Willett CG, Shellito PC, et al: The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. Ann Surg 1998; 228: 194‒200
258）: Strassmann G, Walter S, Kolotas C, et al: Reconstruction and navigation system for intraoperative brachytherapy using the flab technique for colorectal tumor bed irradiation. Int J Radiat Oncol Biol Phys 2000; 47: 1323‒1329
259）: Wong CS, Cummings BJ, Brierley JD, et al: Treatment of locally recurrent rectal carcinoma―results and prognostic factors. Int J Radiat Oncol Biol Phys 1998; 40: 427‒435
260）: Lingareddy V, Ahmad NR, Mohiuddin M: Palliative reirradiation for recurrent rectal cancer. Int J Radiat Oncol Biol Phys 1997; 38: 785‒790
261）: Bates T: A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 1992; 23: 217‒221
262）: Nielsen OS, Munro AJ, Tannock IF: Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9: 509‒524
263）: Wu JS, Wong R, Johnston M, et al; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group: Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55: 594‒605
264）: Chow E, Harris K, Fan G, et al: Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007; 25: 1423‒1436
265）: Nishio M, Sano M, Tamaki Y, et al［: A multicenter study to determine the efficacy and safety of strontium（89Sr）chloride for palliation of painful bony metastases in cancer patients］. ［Article in Japanese］. Nihon Igaku Hoshasen Gakkai Zasshi 2005; 65: 399‒410
266）: Paes FM, Serafini AN: Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010; 40: 89‒104
267）: Cancer pain relief and palliative care: Report of a WHO expert committee. WHO Technical Report Series 804. WHO, Geneva, 1990, 21‒22
268）: 日本緩和医療学会緩和医療ガイドライン委員会編: がん疼痛の薬物療法に関するガイドライン2014 年版，金原出版，東京，2014
269）: Foley KM: The treatment of cancer pain. N Engl J Med 1985; 313: 84‒95
270）: Suzuki K, Gunderson LL, Devine RM, et al: Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. Cancer 1995; 75: 939‒952
271）: Nymann T, Jess P, Christiansen J: Rate and treatment of pelvic recurrence after abdominoperineal resection and low anterior resection for rectal cancer. Dis Colon Rectum 1995; 38: 799‒802
272）: Tong D, Gillick L, Hendrickson FR: The palliation of symptomatic osseous metastases. Final results of the study by the radiation therapy oncology group. Cancer 1982; 50: 893‒899
273）: Helyer LK, Law CH, Butler M, et al: Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol 2007; 14: 1264‒1271
274）: 中田　健，冨田尚裕，岡村　修，他: 切除不能進行癌・再発癌に対する緩和的人工肛門造設術の検討．外科治療2007;96: 101‒105
275）: Law WL, Choi HK, Lee YM, et al: Palliation for advanced malignant colorectal obstruction by self-expanding metallic stents; prospective evaluation of outcomes. Dis Colon Rectum 2004; 47, 39‒43
276）: Khot UP, Lang AW, Murali K, et al: Systemic review of the efficacy and safety of colorectal stents. Br J Surg 2002; 89: 1096‒1102
277）: Baines M, Oliver DJ, Carter RL, et al: Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study. Lancet 2, 990‒993, 1985
278）: Ripamonti C, Twycross R, Baines M, et al: Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001; 9: 223‒233
279）: Maguire P, Walsh S, Jeacock J, et al: Physical and psychological needs of patients dying from colo-rectal cancer. Palliative Medicine 1999; 13: 45‒50
280）: Temel JS, Greer JA, Muzikansky A, et al: Early palliative care for patients with metastatic non‒small-cell lung cancer. N Engl J Med 2010; 363: 733‒742
281）: Sprangers MA, te Verde A, Aaronson NK: The construction and testing of the EORTC Colorectal Cancer-specific Quality of Life Questionnaire Module（QLQ‒CR38）. Eur J Cancer 1999; 35: 238‒247
282）: Uki J, Mendoza T, Charles MS, et al: A brief cancer pain assessment tool in Japanese: The utility of the Japanese Brief Pain Inventory‒BPI‒J. J Pain Symptom Manage 1998; 16: 364‒373
283）: van der Stok EP, Spaander MCW, Grünhagen DJ, et al: Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol 2017; 14: 297‒315
284）: Meyerhardt JA, Mangu PB, Flynn PJ, et al; American Society of Clinical Oncology: Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 2013; 31: 4465‒4470
285）: Mazilu L, Ciufu N, Gălan M, et al: Postherapeutic follow-up of colorectal cancer patients treated with curative intent. Chirurgia（Bucur）2012; 107: 55‒58
286）: Desch CE, Benson AB 3rd, Somerfield MR, et al; American Society of Clinical Oncology: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 2005; 23: 8512‒8519
287）: Labianca R, Nordlinger B, Beretta GD, et al: Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: vi64‒vi72
288）: National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology‒colon cancer, version 3, 2018. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf（accessed 7 August 2018）
289）: 渡辺　正，豊田美知子，伊藤勝基，他: 直腸癌局所再発診断における経時的骨盤部CT 撮影の意義．日本大腸肛門病会誌1989; 42: 1031‒1038
290）: Ramirez JM, Mortensen NJM, Takeuchi N, et al: Endoluminal ultrasonography in the follow-up of patients with rectal cancer. Br J Surg 1994; 81: 692‒694
291）: Löhnert MSS, Doniec JM, Henne-Bruns D: Effectiveness of endoluminal sonography in the identification of occult local rectal cancer recurrences. Dis Colon Rectum 2000; 43: 483‒491
292）: Moore HG, Akhurst T, Larson SM, et al: A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 2003; 197: 22‒28
293）: Flanagan FL, Dehdashti F, Ogunbiyi OA, et al: Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227: 319‒323
294）: Vallam KC, Guruchannabasavaiah B, Agrawal A, et al: Carcinoembryonic antigen directed PET-CECT scanning for postoperative surveillance of colorectal cancer. Colorectal Dis 2017; 19: 907‒911
295）: Kahi CJ, Boland CR, Dominitz JA, et al: Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Gastroenterology. 2016; 150: 758‒768. e11
296）: Rusiecki J, Cifu AS: Colonoscopy surveillance after colorectal cancer resection. JAMA 2017; 318: 2346‒2347
297）: Steele SR, Chang GJ, Hendren S, et al: Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum 2015; 58: 713‒725
298）: Winawer S, Fletcher R, Rex D, et al: Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003; 124: 544‒560
299）: Pickhardt PJ, Edwards K, Bruining DH, et al: Prospective trial evaluating the surgical anastomosis at one-year colorectal cancer surveillance: CT colonography versus optical colonoscopy and implications for patient care. Dis Colon Rectum 2017; 60: 1162‒1167
300）: Porté F, Uppara M, Malietzis G, et al: CT colonography for surveillance of patients with colorectal cancer: Systematic review and meta-analysis of diagnostic efficacy. Eur Radiol 2017; 27: 51‒60
301）: Weinberg DS, Pickhardt PJ, Bruining DH, et al: Computed tomography colonography vs colonoscopy for colorectal cancer surveillance after surgery. Gastroenterology 2018; 154: 927‒934. e4
302）: Renehan AG, Egger M, Saunders MP, et al: Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trial. Br Med J 2002; 324: 813‒816
303）: Figueredo A, Rumble RB, Maroun J, et al: Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 2003; 6: 26
304）: Renehan AG, Egger M, Saunders MP, et al: Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. Br J Cancer 2005; 92: 430‒433
305）: Jeffery M, Hickey BE, Hider PN: Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007; 24: CD002200
306）: Tjandra JJ, Chan MK: Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 2007; 50: 1783‒1799
307）: Pita-Fernández S, Alhayek-Aí M, González-Martín C, et al: Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol 2015; 26: 644‒656
308）: Primrose JN, Perera R, Gray A, et al; FACS Trial Investigators: Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014; 311: 263‒270
309）: Jeffery M, Hickey BE, Hider PN, et al: Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2016; 11: CD002200. Review
310）: Mokhles S, Macbeth F, Farewell V, et al: Meta-analysis of colorectal cancer follow-up after potentially curative resection. Br J Surg 2016; 103: 1259‒1268
311）: Wille-Jørgensen P, Syk I, Smedh K, et al; COLOFOL Study Group: Effect of more vs less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage Ⅱ or Ⅲ colorectal cancer: The COLOFOL randomized clinical trial. JAMA 2018; 319: 2095‒2103
312）: Tsikitis VL, Malireddy K, Green EA, et al: Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol 2009; 27: 3671‒3676
313）: Metcalfe MS, Mullin EJ, Maddern GJ: Choice of surveillance after hepatectomy for colorectal metastases. Arch Surg 2004; 139: 749‒754
314）: Hyder O, Dodson RM, Mayo SC, et al: Post-treatment surveillance of patients with colorectal cancer with surgically treated liver metastases. Surgery 2013; 154: 256‒265
315）: Okamura R, Hida K, Nishizaki D, et al: Proposal of a stage-specific surveillance strategy for colorectal cancer patients: A retrospective analysis of Japanese large cohort. Eur J Surg Oncol 2018; 44: 449‒455
316）: Green RJ, Metlay JP, Propert K, et al: Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002; 136: 261‒269
317）: 石黒めぐみ，望月英隆，杉原健一，他: 大腸癌に合併する多発癌・重複がんに関するフォローアップについて．日本大腸肛門病会誌2006; 59: 863‒868
318）: Berman J, Cheung R, Weiberg D: Surveillance after colorectal cancer resection. Lancet 2000; 355: 395‒399
319）: Ueno H, Mochizuki H, Hashiguchi Y, et al: Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127: 385‒394
320）: Kitajima K, Fujimori T, Fujii S, et al: Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 2004; 39: 534‒543
321）: 武田　純，長廻　紘，奥山　隆，他: 5．大腸sm 癌の取り扱い．b．内視鏡治療後の追加手術が必要な条件．武藤徹一郎（監），渡辺英伸，杉原健一，多田正大（編），大腸疾患NOW 2004，日本メディカルセンター，東京，2004: 60‒69
322）: Tanaka S, Haruma K, Oh-e H, et al: Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep 2000; 7: 783‒788
323）: 大腸癌研究会編: 大腸癌取扱い規約，第2 版，金原出版，東京，1980
324）: 大腸癌研究会編: 大腸癌取扱い規約，第5 版，金原出版，東京，1994
325）: 大腸癌研究会編: 大腸癌治療ガイドライン―医師用2005 年版，金原出版，東京，2005
326）: 味岡洋一，大倉康男，池上雅博，他: 早期大腸癌の内視鏡治療の適応拡大　（1）T1b 癌（1,000μ以深SM 癌）リンパ節転移リスク層別化の検討．大腸疾患NOW 2016，日本メディカルセンター，東京，2016: 63‒77
327）: 大腸癌研究会編: 大腸癌治療ガイドライン―医師用2009 年版，金原出版，東京，2009
328）: Matsuda T, Fukuzawa M, Uraoka T, et al: Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: a retrospective multicenter study. Cancer Sci 2011; 102: 1693‒1697
329）: Ikematsu H, Yoda Y, Matsuda T, et al: Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroenterology 2013; 144: 551‒559; quiz e14
330）: Tamaru Y, Oka S, Tanaka S, et al: Long-term outcomes after treatment for T1 colorectal carcinoma: a multicenter retrospective cohort study of Hiroshima GI Endoscopy Research Group. J Gastroenterol 2017; 52: 1169‒1179
331）: Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al: Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy（ESGE）Guideline. Endoscopy 2015; 47: 829‒854
332）: Moss A, Bourke MJ, Metz AJ: A randomized, double-blind trial of succinylated gelatin submucosal injection for endoscopic resection of large sessile polyps of the colon. Am J Gastroenterol 2010; 105: 2375‒2382
333）: Tanaka S, Terasaki M, Hayashi N, et al: Warning for unprincipled colorectal endoscopic submucosal dissection: accurate diagnosis and reasonable treatment strategy. Dig Endosc 2013; 25: 107‒116
334）: Uraoka T, Saito Y, Matsuda T, et al: Endoscopic indications for endoscopic mucosal resection of laterally spreading tumours in the colorectum. Gut 2006; 55: 1592‒1597. Epub 2006 May 8
335）: Tanaka S, Haruma K, Oka S, et al: Clinicopathologic features and endoscopic treatment of superficially spreading colorectal neoplasms larger than 20 mm. Gastrointest Endosc 2001; 54: 62‒66
336）: Saito Y, Fukuzawa M, Matsuda T, et al: Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection. Surg Endosc 2010; 24: 343‒352
337）: Kudo S, Hirota S, Nakajima T, et al: Colorectal tumours and pit pattern. J Clin Pathol 1994; 47: 880‒885
338）: Kiriyama S, Saito Y, Yamamoto S, et al: Comparison of endoscopic submucosal dissection with laparoscopic-assisted colorectal surgery for early-stage colorectal cancer: a retrospective analysis. Endoscopy 2012; 44: 1024‒1030
339）: Takeuchi Y, Iishi H, Tanaka S, et al: Factors associated with technical difficulties and adverse events of colorectal endoscopic submucosal dissection: retrospective exploratory factor analysis of a multicenter prospective cohort. Int J Colorectal Dis 2014; 29: 1275‒1284
340）: Wada Y, Kudo SE, Tanaka S, et al: Predictive factors for complications in endoscopic resection of large colorectal lesions: a multicenter prospective study. Surg Endosc 2015; 29: 1216‒1222
341）: Nakajima T, Saito Y, Tanaka S, et al: Current status of endoscopic resection strategy for large, early colorectal neoplasia in Japan. Surg Endosc 2013; 27: 3262‒3270
342）: Yamada M, Saito Y, Sakamoto T, et al: Endoscopic predictors of deep submucosal invasion in colorectal laterally spreading tumors. Endoscopy 2016; 48: 456‒464
343）: Yamada M, Saito Y, Takamaru H, et al: Long-term clinical outcomes of endoscopic submucosal dissection for colorectal neoplasms in 423 cases: a retrospective study. Endoscopy 2017; 49: 233‒242
344）: Takamaru H, Saito Y, Yamada M, et al: Clinical impact of endoscopic clip closure of perforations during endoscopic submucosal dissection for colorectal tumors. Gastrointest Endosc 2016; 84: 494‒502. e1
345）: Lieberman DA, Weiss DG, Harford WV, et al: Five-year colon surveillance after screening colonoscopy. Gastroenterology 2007; 133: 1077‒1085
346）: Zauber AG, Winawer SJ, O’Brien MJ, et al: Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366: 687‒696
347）: Cottet V, Jooste V, Fournel I, et al: Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. Gut 2012; 61: 1180‒1186
348）: Lieberman DA, Rex DK, Winawer SJ, et al: Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143: 844‒857
349）: Hassan C, Quintero E, Dumonceau JM, et al; European Society of Gastrointestinal Endoscopy: Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy（ESGE）Guideline. Endoscopy 2013; 45: 842‒851
350）: Yoshida N, Naito Y, Siah KT, et al: High incidence of metachronous advanced adenoma and cancer after endoscopic resection of colon polyps＞/＝20 mm in size. Dig Endosc 2016; 28: 194‒202
351）: Matsuda T, Fujii T, Sano Y, et al: Five-year incidence of advanced neoplasia after initial colonoscopy in Japan: a multicenter retrospective cohort study. Jpn J Clin Oncol 2009; 39: 435‒442
352）: Hotta K, Fujii T, Saito Y, et al: Local recurrence after endoscopic resection of colorectal tumors. Int J Colorectal Dis 2009; 24: 225‒230
353）: Moss A, Williams SJ, Hourigan LF, et al: Long-term adenoma recurrence following wide-field endoscopic mucosal resection（WF-EMR）for advanced colonic mucosal neoplasia is infrequent: results and risk factors in 1000 cases from the Australian Colonic EMR（ACE）study. Gut 2015; 64: 57‒65
354）: Oka S, Tanaka S, Saito Y, et al; Colorectal Endoscopic Resection Standardization Implementation Working Group of the Japanese Society for Cancer of the Colon and Rectum, Tokyo, Japan: Local recurrence after endoscopic resection for large colorectal neoplasia: a multicenter prospective study in Japan. Am J Gastroenterol 2015; 110: 697‒707
355）: Niimi K, Fujishiro M, Kodashima S, et al: Long-term outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms. Endoscopy 2010; 42: 723‒729
356）: Shigita K, Oka S, Tanaka S, et al: Long-term outcomes after endoscopic submucosal dissection for superficial colorectal tumors. Gastrointest Endosc 2017; 85: 546‒553
357）: le Clercq CM, Bouwens MW, Rondagh EJ, et al: Postcolonoscopy colorectal cancers are preventable: a population-based study. Gut 2014; 63: 957‒963
358）: Kim JS, Kang SH, Moon HS, et al: Impact of bowel preparation quality on adenoma identification during colonoscopy and optimal timing of surveillance. Dig Dis Sci 2015; 60: 3092‒3099
359）: Yoda Y, Ikematsu H, Matsuda T, et al: A large-scale multicenter study of long-term outcomes after endoscopic resection for submucosal invasive colorectal cancer. Endoscopy 2013; 45: 718‒724
360）: Lacy AM, García-Valdecasas JC, Delgado S, et al: Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 2002; 359: 2224‒2229
361）: Weeks JC, Nelson H, Gelber S, et al; Clinical Outcomes of Surgical Therapy（COST）Study Group: Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA 2002; 287: 321‒328
362）: Clinical Outcomes of Surgical Therapy Study Group, Nelson H, Sargent DJ, Wieand HS, et al: A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350: 2050‒2059
363）: Veldkamp R, Kuhry E, Hop WC, et al; COlon Cancer Laparoscopic or Open Resection Study Group（COLOR）: Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol 2005; 6: 477‒484
364）: Leung KL, Kwok SP, Lam SC, et al: Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. Lancet 2004; 363: 1187‒1192
365）: Schwenk W, Haase O, Neudecker J, et al: Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev 2005; 20: CD003145. Review
366）: Guillou PJ, Quirke P, Thorpe H, et al; MRC CLASICC trial group: Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer（MRC CLASICC trial）: multicentre, randomised controlled trial. Lancet 2005; 365: 1718‒1726
367）: Yamamoto S, Inomata M, Katayama H, et al; Japan Clinical Oncology Group Colorectal Cancer Study Group: Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage Ⅱ/Ⅲ colon cancer: Japan Clinical Oncology Group Study JCOG 0404. Ann Surg 2014; 260: 23‒30
368）: Jayne DG, Guillou PJ, Thorpe H, et al; UK MRC CLASICC Trial Group: Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol 2007; 25: 3061‒3068
369）: Colon Cancer Laparoscopic or Open Resection Study Group, Buunen M, Veldkamp R, Hop WC, et al: Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol 2009; 10: 44‒52
370）: Kuhry E, Schwenk WF, Gaupset R, et al: Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008;（2）: CD003432
371）: Green BL, Marshall HC, Collinson F, et al: Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg 2013; 100: 75‒82
372）: Kitano S, Inomata M, Mizusawa J, et al: Survival outcomes following laparoscopic versus open D3 dissection for stage Ⅱ or Ⅲ colon cancer（JCOG0404）: a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2017; 2: 261‒268
373）: Kitano S, Inomata M, Sato A, et al; Japan Clinical Oncology Group Study: Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan Clinical Oncology Group Study JCOG 0404. Jpn J Clin Oncol 2005; 35: 475‒477
374）: Senagore AJ, Delaney CP, Madboulay K, et al: Laparoscopic colectomy in obese and nonobese patients. J Gastrointest Surg 2003; 7: 558‒561
375）: Lascano CA, Kaidar-Person O, Szomstein S, et al: Challenges of laparoscopic colectomy in the obese patient: a review. Am J Surg 2006; 192: 357‒365
376）: Arteaga González I, Martín Malagón A, López-Tomassetti Fernández EM, et al: Impact of previous abdominal surgery on colorectal laparoscopy results: a comparative clinical study. Surg Laparosc Endosc Percutan Tech 2006; 16: 8‒11
377）: Kang SB, Park JW, Jeong SY, et al: Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy（COREAN trial）: short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 2010; 11: 637‒645
378）: van der Pas MH, Haglind E, Cuesta MA, et al; COlorectal cancer Laparoscopic or Open Resection Ⅱ（COLOR Ⅱ）Study Group: Laparoscopic versus open surgery for rectal cancer（COLOR Ⅱ）: short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013; 14: 210‒218
379）: Bonjer HJ, Deijen CL, Abis GA, et al; COLOR Ⅱ Study Group: A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 2015; 372: 1324‒1332
380）: Jeong SY, Park JW, Nam BH, et al: Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy（COREAN trial）: survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 2014; 15: 767‒774
381）: Stevenson AR, Solomon MJ, Lumley JW, et al; ALaCaRT Investigators: Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: The ALaCaRT randomized clinical trial. JAMA 2015; 314: 1356‒1363
382）: Fleshman J, Branda M, Sargent DJ, et al: Effect of laparoscopic-assisted resection vs open resection of stage Ⅱ or Ⅲ rectal cancer on pathologic outcomes: The ACOSOG Z6051 randomized clinical trial. JAMA 2015; 314: 1346‒1355
383）: Speicher PJ, Englum BR, Ganapathi AM, et al: Robotic low anterior resection for rectal cancer: a national perspective on short-term oncologic outcomes. Ann Surg 2015; 262: 1040‒1045
384）: Kim CW, Kim CH, Baik SH: Outcomes of robotic-assisted colorectal surgery compared with laparoscopic and open surgery: a systematic review. J Gastrointest Surg 2014; 18: 816‒830
385）: Wang Y, Zhao GH, Yang H, et al: A pooled analysis of robotic versus laparoscopic surgery for total mesorectal excision for rectal cancer. Surg Laparosc Endosc Percutan Tech 2016; 26: 259‒264
386）: Broholm M, Pommergaard HC, Gögenür I: Possible benefits of robot-assisted rectal cancer surgery regarding urological and sexual dysfunction: a systematic review and meta-analysis. Colorectal Dis 2015; 17: 375‒381
387）: Hojo K, Koyama Y, Moriya Y. Lymphatic spread and its prognostic value in patients with rectal cancer. Am J Surg 1982; 144: 350‒354
388）: Moriya Y, Hojo K, Sawada T, et al: Significance of lateral node dissection for advanced rectal carcinoma at or below the peritoneal reflection. Dis Colon Rectum 1989; 32: 307‒315
389）: Sugihara K, Moriya Y, Akasu T, et al: Pelvic autonomic nerve preservation for patients with rectal carcinoma. Oncologic and functional outcome. Cancer 1996; 78: 1871‒1880
390）: Takahashi T, Ueno M, Azekura K, et al: Lateral node dissection and total mesorectal excision for rectal cancer. Dis Colon Rectum. Dis Colon Rectum 2000; 43: S59‒S68. Review
391）: Mori T, Takahashi K, Yasuno M: Radical resection with autonomic nerve preservation and lymph node dissection techniques in lower rectal cancer surgery and its results: the impact of lateral lymph node dissection. Langenbecks Arch Surg 1998; 383: 409‒415
392）: Ueno H, Mochizuki H, Hashiguchi Y, et al: Prognostic determinant of patients with lateral nodal involvement by rectal cancer. Ann Surg 2001; 234: 190‒197
393）: Ueno M, Oya M, Azekura K, et al: Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. Br J Surg 2005; 92: 756‒763
394）: Kanemitsu Y, Komori K, Shida D, et al: Potential impact of lateral lymph node dissection（LLND）for low rectal cancer on prognoses and local control: A comparison of 2 high-volume centers in Japan that employ different policies concerning LLND. Surgery 2017; 162: 303‒314
395）: Ueno H, Mochizuki H, Hashiguchi Y, et al: Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below teh peritoneal reflection. Ann Surg 2007; 245: 80‒87
396）: Akiyoshi T, Watanabe T, Miyata S, et al; Japanese Society for Cancer of the Colon and Rectum: Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg 2012; 255: 1129‒1134
397）: Ozawa H, Kotake K, Hosaka M, et al: Impact of lateral pelvic lymph node dissection on the survival of patients with T3 and T4 low rectal cancer. World J Surg 2016; 40: 1492‒1499
398）: Oh HK, Kang SB, Lee SM, et al: Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study. Ann Surg Oncol 2014; 21: 2280‒2287
399）: Akiyoshi T, Matsueda K, Hiratsuka M, et al: Indications for lateral pelvic lymph node dissection based on magnetic resonance imaging before and after preoperative chemoradiotherapy in patients with advanced low-rectal cancer. Ann Surg Oncol 2015; 22: S614‒620
400）: Fujita S, Mizusawa J, Kanemitsu Y, et al; Colorectal Cancer Study Group of Japan Clinical Oncology Group: Mesorectal excision with or without lateral lymph node dissection for clinical stage Ⅱ/Ⅲ lower rectal cancer（JCOG0212）: a multicenter, randomized controlled, noninferiority trial. Ann Surg 2017; 266: 201‒207
401）: Nagawa H, Muto T, Sunouchi K, et al: Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy. Dis Colon Rectum 2001; 44: 1274‒1280
402）: Ogawa S, Hida J, Ike H, et al: Selection of lymph node‒positive cases based on perirectal and lateral pelvic lymph nodes using magnetic resonance imaging: study of the Japanese Society for Cancer of the Colon and Rectum. Ann Surg Oncol 2016; 23: 1187‒1194
403）: National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology‒rectal cancer, version 1, 2008. http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf（accessed 28 March 2008）
404）: Stillwell AP, Buettner PG, Ho YH: Meta-analysis of survival of patients with stage Ⅳ colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 2010; 34: 797‒807
405）: Cummins ER, Vick KD, Poole GV: Incurable colorectal carcinoma: The role of surgical palliation. Am Surgeon 2004; 70: 433‒437
406）: Seo GJ, Park JW, Yoo SB, et al: Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage Ⅳ colorectal cancer. J Surg Oncol 2010; 102: 94‒99
407）: Aslam MI, Kelkar A, Sharpe D, et al: Ten years experience of managing the primary tumours in patients with stage Ⅳ colorectal cancers. Int J Surg 2010; 8: 305‒313
408）: McCahill LE, Yothers G, Sharif S, et al: Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C‒10. J Clin Oncol 2012; 30: 3223‒3228
409）: Law WL, Chan WF, Lee YM, et al: Non-curative surgery for colorectal cancer: critical appraisal of outcomes. Int J Colorectal Dis 2004; 19: 197‒202
410）: Konyalian VR, Rosing DK, Haukoos JS, et al: The role of primary tumour resection in patients with stage Ⅳ colorectal cancer. Colorectal Dis 2007; 9: 430‒437
411）: Shida D, Hamaguchi T, Ochiai H, et al: Prognostic impact of palliative primary tumor resection for unresectable stage 4 colorectal cancer: Using a propensity score analysis. Ann Surg Oncol 2016; 23: 3602‒3608
412）: Ishihara S, Hayama T, Yamada H, et al: Prognostic impact of primary tumor resection and lymph node dissection in stage Ⅳ colorectal cancer with unresectable metastasis: a propensity score analysis in a multicenter retrospective study. Ann Surg Oncol 2014; 21: 2949‒2955
413）: Tarantino I, Warschkow R, Worni M, et al: Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal cancer patients: a population-based, propensity score-adjusted trend analysis. Ann Surg 2015; 262: 112‒120
414）: Sarela AI, Guthrie JA, Seymour MT, et al: Non-operative management of the primary tumour in patients with incurable stage Ⅳ colorectal cancer. Br J Surg 2001; 88: 1352‒1356
415）: Muratore A, Zorzi D, Bouzari H, et al: Asymptomatic colorectal cancer with un-resectable liver metastasis: Immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2006; 14: 766‒770
416）: Mentha G, Majno PE, Andres A, et al: Neoadjuvant chemotherapy and resection of advanced synchronous liver metastasis before treatment of the colorectal primary. Br J Surg 2006; 93: 872‒878
417）: Cirocchi R, Trastulli S, Abraha I, et al: Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage Ⅳ colorectal cancer. Cochrane Database Syst Rev 2012; CD008997
418）: Rahbari NN, Lordick F, Fink C, et al; SYNCHRONOUS trial group: Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases（UICC stage Ⅳ）: SYNCHRONOUS‒‒a randomised controlled multicentre trial（ISRCTN30964555）. BMC Cancer 2012; 12: 142
419）: ’t Lam-Boer J, Mol L, Verhoef C, et al: The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer‒‒a randomized phase Ⅲ study of the Dutch Colorectal Cancer Group（DCCG）. BMC Cancer 2014; 14: 741
420）: Kim CW, Baek JH, Choi GS, et al: The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial. Trials 2016; 17: 34
421）: Rosen SA, Buell JF, Yoshida A, et al: Initial presentation with stage Ⅳ colorectal cancer. How aggressive should we be? Arch Surg 2000; 135: 530‒535
422）: Pestieau SR, Sugarbaker PH: Treatment of primary colon cancer with peritoneal carcinomatosis comparison of concomitant vs. delayed management. Dis Colon Rectum 2000; 43: 1341‒1346; discussion 1347‒1348
423）: Ozawa H, Kotake K, Kobayashi H, et al: Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database. Surg Today 2014; 44: 1643‒1650
424）: Shida D, Tsukamoto S, Ochiai H, et al: Long-term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2018; 25: 173‒178
425）: Shida D, Yoshida T, Tanabe T, et al: Prognostic impact of R0 resection and targeted therapy for colorectal cancer with synchronous peritoneal metastasis. Ann Surg Oncol 2018; 25: 1646‒1653
426）: Kobayashi H, Kotake K, Funahashi K, et al; Study Group for Peritoneal Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum: Clinical benefit of surgery for stage Ⅳ colorectal cancer with synchronous peritoneal metastasis. J Gastroenterol 2014; 49: 646‒654
427）: Kobayashi H, Kotake K, Sugihara K: Outcomes of surgery without HIPEC for synchronous peritoneal metastasis from colorectal cancer: data from a multi-center registry. Int J Clin Oncol 2014; 19: 98‒105
428）: Huang CQ, Yang XJ, Yu Y, et al: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase Ⅱ study from a Chinese center. PLoS One 2014; 9: e108509
429）: Goéré D, Malka D, Tzanis D, et al: Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 2013; 257: 1065‒1071
430）: Nikolic S, Dzodic R, Zegarac M, et al: Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience. J BUON 2014; 19: 66‒74
431）: Ambiru S, Miyazaki M, Ito H, et al: Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998; 82: 274‒278
432）: Shah SA, Haddad R, Al-Sukhni W, et al: Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006; 202: 468‒475
433）: 服部憲史，金光幸秀，小森康司，他: 大腸癌肝・肺転移切除例の検討―肺転移単独と肝肺2 臓器転移との比較―．癌の臨床2010; 56: 789‒796
434）: Adam R, de Haas RJ, Wicherts DA, et al: Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery? Ann Surg 2011; 253: 349‒359
435）: Gonzalez M, Robert JH, Halkic N, et al: Survival after lung metastasectomy in colorectal cancer patients with previously resected liver metastases. World J Surg 2012; 36: 386‒391
436）: Mise Y, Kopetz S, Mehran RJ, et al: Is complete liver resection without resection of synchronous lung metastases justified? Ann Surg Oncol 2015; 22: 1585‒1592
437）: Salah S, Ardissone F, Gonzalez M, et al: Pulmonary metastasectomy in colorectal cancer patients with previously resected liver metastasis: pooled analysis. Ann Surg Oncol 2015; 22: 1844‒1850
438）: Nagakura S, Shirai Y, Yamato Y, et al: Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. J Am Coll Surg 2001; 193: 153‒160
439）: Mineo TC, Ambrogi V, Tonini G, et al: Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg 2003; 197: 386‒391
440）: Limmer S, Oevermann E, Killaitis C, et al: Sequential surgical resection of hepatic and pulmonary metastases from colorectal cancer. Langenbecks Arch Surg 2010; 395: 1129‒1138
441）: Brouquet A, Vauthey JN, Contreras CM, et al: Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease. J Am Coll Surg 2011; 213: 62‒69
442）: Ayez N, Lalmahomed ZS, Eggermont AM, et al: Outcome of microscopic incomplete resection（R1）of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol 2012; 19: 1618‒1627
443）: Viganò L, Capussotti L, Barroso E, et al: Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases. Ann Surg Oncol 2012; 19: 2786‒2796
444）: Reissfelder C, Brand K, Sobiegalla J, et al: Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases. Surgery 2014; 155: 245‒254
445）: Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052‒1061; discussion 1061‒1064
446）: Rahman S, Toogood GJ, Lodge PJ, et al: Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver（Br J Surg 2003; 90: 963‒969）. Br J Surg 2003; 90: 1453
447）: Ayez N, van der Stok EP, de Wilt H, et al: Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. BMC Cancer 2015; 15: 180
448）: Nordlinger B, Sorbye H, Glimelius B, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und‒tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie（ALM‒CAO）; Australasian Gastro-Intestinal Trials Group（AGITG）; Fédération Francophone de Cancérologie Digestive（FFCD）: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer（EORTC Intergroup trial 40983）: a randomised controlled trial. Lancet 2008;371: 1007‒1016
449）: Primrose J, Falk S, Finch-Jones M, et al: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014; 15: 601‒611
450）: Van Cutsem E, Cervantes A, Adam R, et al: ESMO consensus guidelines for the mana gement of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27: 1386‒1342
451）: Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311‒1319
452）: Folprecht G, Gruenberger T, Bechstein WO, et al: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38‒47
453）: Hatano E, Okuno M, Nakamura K, et al: Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis（BECK study）. J Hepatobiliary Pancreat Sci 2015; 22: 634‒645
454）: Okines A, Puerto OD, Cunningham D, et al: Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-Ⅲ NO16966 trial. Br J Cancer 2009; 101: 1033‒1038
455）: Delaunoit T, Alberts SR, Sargent DJ, et al: Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005; 16: 425‒429
456）: Bismuth H, Adam R, Lévi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509‒520
457）: Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644‒657
458）: Nuzzo G, Giuliante F, Ardito F, et al: Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 2007; 11: 318‒324
459）: Robinson SM, Wilson CH, Burt AD, et al: Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 4287‒4299
460）: Zhao J, van Mierlo KMC, Gómez-Ramírez J, et al; Chemotherapy-Associated Liver Injury（CALI）consortium: Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg 2017; 104: 990‒1002
461）: Li WH, Peng JJ, Xiang JQ, et al: Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer. World J Gastroenterol 2010; 16: 3318‒3324
462）: Goéré D, Gaujoux S, Deschamp F, et al: Patients operated on for initially unresectable colorectal liver metastases with missing metastases experience a favorable long-term outcome. Ann Surg 2011; 254: 114‒118
463）: Adam R, Wicherts DA, de Haas RJ, et al: Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26: 1635‒1641
464）: van Vledder MG, de Jong MC, Pawlik TM, et al: Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 2010; 14: 1691‒1700
465）: Auer RC, White RR, Kemeny NE, et al: Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116: 1502‒1509
466）: Benoist S, Brouquet A, Penna C, et al: Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24: 3939‒3945
467）: Elias D, Goere D, Boige V, et al: Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14: 3188‒3194. Epub 2007 Aug 20
468）: Arita J, Ono Y, Takahashi M, et al: Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy. Ann Surg Oncol 2014; 21: S390‒397
469）: Allen PJ, Kemeny N, Jarnagin W, et al: Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003; 7: 109‒117
470）: Evrard S, Poston G, Kissmeyer-Nielsen P, et al: Combined ablation and resection（CARe）as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One 2014; 9: e114404
471）: Evrard S, Audisio R, Poston G, et al: From a comic opera to surcare an open letter to whom clinical research in surgery is a concern: announcing the launch of SURCARE. Ann Surg 2016; 264: 911‒912
472）: Kataoka K, Nakamura K, Caballero C, et al: Collaboration between EORTC and JCOG‒how to accelerate global clinical research partnership. Jpn J Clin Oncol 2017; 47: 164‒169
473）: Beppu T, Wakabayashi G, Hasegawa K, et al: Long-term and perioperative outcomes of laparoscopic versus open liver resection for colorectal liver metastases with propensity score matching: a multi-institutional Japanese study. J Hepatobiliary Pancreat Sci 2015; 22: 711‒720
474）: Schiffman SC, Kim KH, Tsung A, et al: Laparoscopic versus open liver resection for metastatic colorectal cancer: a metaanalysis of 610 patients. Surgery 2015; 157: 211‒222
475）: Nguyen KT, Laurent A, Dagher I, et al: Minimally invasive liver resection for metastatic colorectal cancer: a multiinstitutional, international report of safety, feasibility, and early outcomes. Ann Surg 2009; 250: 842‒848
476）: Castaing D, Vibert E, Ricca L, et al: Oncologic results of laparoscopic versus open hepatectomy for colorectal liver metastases in two specialized centers. Ann Surg 2009; 250: 849‒855
477）: Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, et al: Laparoscopic versus open resection for colorectal liver metastases: The OSLO‒COMET randomized controlled trial. Ann Surg 2018; 267: 199‒207
478）: Takahara T, Wakabayashi G, Konno H, et al: Comparison of laparoscopic major hepatectomy with propensity score matched open cases from the National Clinical Database in Japan. J Hepatobiliary Pancreat Sci 2016; 23: 721‒734
479）: Huh JW, Koh YS, Kim HR, et al: Comparison of laparoscopic and open colorectal resections for patients undergoing simultaneous R0 resection for liver metastases. Surg Endosc 2011; 25: 193‒198
480）: Welsh FK, Tekkis PP, John TG, et al: Open liver resection for colorectal metastases: better short- and long-term outcomes in patients potentially suitable for laparoscopic liver resection. HPB（Oxford）2010; 12: 188‒194
481）: Vigano L, Laurent A, Tayar C, et al: The learning curve in laparoscopic liver resection: improved feasibility and reproducibility. Ann Surg 2009; 250: 772‒782
482）: Ban D, Tanabe M, Ito H, et al: A novel difficulty scoring system for laparoscopic liver resection. J Hepatobiliary Pancreat Sci 2014; 21: 745‒753
483）: Cho JY, Han HS, Yoon YS, et al: Experiences of laparoscopic liver resection including lesions in the posterosuperior segments of the liver. Surg Endosc 2008; 22: 2344‒2349
484）: Ikeda T, Toshima T, Harimoto N, et al: Laparoscopic liver resection in the semiprone position for tumors in the anterosuperior and posterior segments, using a novel dual-handling technique and bipolar irrigation system. Surg Endosc 2014; 28: 2484‒2492
485）: Halls MC, Cherqui D, Taylor MA, et al; Collaborators of The Difficulty of Laparoscopic Liver Surgery Survey: Are the current difficulty scores for laparoscopic liver surgery telling the whole story? An international survey and recommendations for the future. HPB（Oxford）2018; 20: 231‒236
486）: Mulier S, Ruers T, Jamart J, et al: Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? An update. Dig Surg 2008; 25: 445‒460
487）: Berber E, Siperstein A: Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol 2008; 15: 2757‒2764
488）: Elias D, Baton O, Sideris L, et al: Local recurrences after intraoperative radiofrequency ablation of liver metastases: a comparative study with anatomic and wedge resections. Ann Surg Oncol 2004; 11: 500‒505
489）: Weng M, Zhang Y, Zhou D, et al: Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. PLoS One 2012; 7: e45493
490）: Park IJ, Kim HC, Yu CS, et al: Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol 2008; 15: 227‒232
491）: Berber E, Tsinberg M, Tellioglu G, et al: Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 2008; 12: 1967‒1972
492）: Ruers T, Punt C, Van Coevorden F, et al: EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und‒tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie（ALM‒CAO）and the National Cancer Research Institute Colorectal Clinical Study Group（NCRI CCSG）: Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase Ⅱ study（EORTC 40004）. Ann Oncol 2012; 23: 2619‒2626
493）: Wanebo HJ, Koness RJ, Vezeridis MP, et al: Pelvic resection of recurrent rectal cancer. Ann Surg 1994; 220: 586‒595; discussion 595‒597
494）: Moriya Y, Akasu T, Fujita S, et al: Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer in the pelvis. Dis Colon Rectum 2004; 47: 2047‒2053
495）: Yamada K, Ishizawa T, Niwa K, et al: Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer. Br J Surg 2001; 88: 988‒993
496）: Saito N, Koda K, Takiguchi N, et al: Curative surgery for local pelvic recurrence of rectal cancer. Dig Surg 2003; 20: 192‒199
497）: Kanemitsu Y, Hirai T, Komori K, et al: Prediction of residual disease or distant metastasis after resection of locally recurrent rectal cancer. Dis Colon Rectum 2010; 53: 779‒789
498）: Ogawa H, Uemura M, Nishimura J, et al: Preoperative chemoradiation followed by extensive pelvic surgery improved the outcome of posterior invasive locally recurrent rectal cancer without deteriorating surgical morbidities: a retrospective, single-institution analysis. Ann Surg Oncol 2015; 22: 4325‒4334
499）: Nielsen MB, Rasmussen PC, Lindegaard JC, et al: A 10-year experience of total pelvic exenteration for primary advanced and locally recurrent rectal cancer based on a prospective database. Colorectal Dis 2012; 14: 1076‒1083
500）: Ghouti L, Pereira P, Filleron T, et al: Pelvic exenterations for specific extraluminal recurrences in the era of total mesorectal excision: is there still a chance for cure?: a single-center review of patients with extraluminal pelvic recurrence for rectal cancer from March 2004 to November 2010. Am J Surg 2015; 209: 352‒362
501）: Harris CA, Solomon MJ, Heriot AG, et al: The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg 2016; 264: 323‒329
502）: Pellino G, Sciaudone G, Candilio G, et al: Effect of surgery on health-related quality of life of patients with locally recurrent rectal cancer. Dis Colon Rectum 2015; 58: 753‒761
503）: Kusters M, Dresen RC, Martijn H, et al: Radicality of resection and survival after multimodality treatment is influenced by subsite of locally recurrent rectal cancer. Int J Radiat Oncol Biol Phys 2009; 75: 1444‒1449
504）: Uehara K, Ito Z, Yoshino Y, et al: Aggressive surgical treatment with bony pelvic resection for locally recurrent rectal cancer. Eur J Surg Oncol 2015; 41: 413‒420
505）: Bosman SJ, Vermeer TA, Dudink RL, et al: Abdominosacral resection: long-term outcome in 86 patients with locally advanced or locally recurrent rectal cancer. Eur J Surg Oncol 2014; 40: 699‒705
506）: Colibaseanu DT, Dozois EJ, Mathis KL, et al: Extended sacropelvic resection for locally recurrent rectal cancer: can it be done safely and with good oncologic outcomes? Dis Colon Rectum 2014; 57: 47‒55
507）: Milne T, Solomon MJ, Lee P, et al: Assessing the impact of a sacral resection on morbidity and survival after extended radical surgery for locally recurrent rectal cancer. Ann Surg 2013; 258: 1007‒1013
508）: Austin KK, Herd AJ, Solomon MJ, et al: Outcomes of pelvic exenteration with en bloc partial or complete pubic bone excision for locally advanced primary or recurrent pelvic cancer. Dis Colon Rectum 2016; 59: 831‒835
509）: Hartley JE, Lopez RA, Paty PB, et al: Resection of locally recurrent colorectal cancer in the presence of distant metastases: can it be justified? Ann Surg Oncol 2003; 10: 227‒233
510）: Vermaas M, Ferenschild FT, Nuyttens JJ, et al: Preoperative radiotherapy improves outcome in recurrent rectal cancer. Dis Colon Rectum 2005; 48: 918‒928
511）: Holman FA, Bosman SJ, Haddock MG, et al: Results of a pooled analysis of IOERT containing multimodality treat ment for locally recurrent rectal cancer: Results of 565 patients of two major treatment centres. Eur J Surg Oncol 2017; 43: 107‒117
512）: Haddock MG, Gunderson LL, Nelson H, et al: Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients. Int J Radiat Oncol Biol Phys 2001; 49: 1267‒1274
513）: Mohiuddin M, Marks G, Marks J: Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer 2002; 95: 1144‒1150
514）: Rombouts AJ, Koh CE, Young JM, et al: Does radiotherapy of the primary rectal cancer affect prognosis after pelvic exenteration for recurrent rectal cancer? Dis Colon Rectum 2015; 58: 65‒73
515）: Gunderson LL, Nelson H, Martenson JA, et al: Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation＋/－5-FU. Int J Radiat Oncol Biol Phys 1997; 37: 601‒614
516）: Gunderson LL, Nelson H, Martenson JA, et al: Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer. Dis Colon Rectum 1996; 39: 1379‒1395
517）: Dresen RC, Gosens MJ, Martijn H, et al: Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer. Ann Surg Oncol 2008; 15: 1937‒1947
518）: Hashiguchi Y, Sekine T, Kato S, et al: Indicators for surgical resection and intraoperative radiation therapy for pelvic recurrence of colorectal cancer. Dis Colon Rectum 2003; 46: 31‒39
519）: Yamada S, Kamada T, Ebner DK, et al; Working Group on Locally Recurrent Rectal Cancer: Carbon-ion radiation therapy for pelvic recurrence of rectal cancer. Int J Radiat Oncol Biol Phys 2016; 96: 93‒101
520）: Kuebler JP, Wieand HS, O’Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage Ⅱ and Ⅲ colon cancer: results from NSABP C‒07. J Clin Oncol 2007; 25: 2198‒2204
521）: André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage Ⅱ or Ⅲ colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109‒3116
522）: Yothers G, O’Connell MJ, Allegra CJ, et al: Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C‒07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768‒3774
523）: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials（IMPACT）investigators. Lancet 1995; 345: 939‒944
524）: Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage Ⅲ colon cancer. N Engl J Med 2005; 352: 2696‒2704
525）: Lembersky BC, Wieand HS, Petrelli NJ, et al: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage Ⅱ and Ⅲ carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C‒06. J Clin Oncol 2006; 24: 2059‒2064
526）: Hamaguchi T, Shimada Y, Mizusawa J, et al: Randomized phase Ⅲ study of adjuvant chemotherapy with S-1 versus capecitabine（cape）in patients with stage Ⅲ colon cancer（CC）: Results of Japan Clinical Oncology Group Study（JCOG0910）. 2015 ASCO Annual Meeting; J Clin Oncol 33, 2015（suppl: abstr 3512）
527）: Kotaka M, Yoshino T, Oba K, et al: Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage Ⅱ or Ⅲ colon cancer（JFMC41‒1001‒C2: JOIN trial）. Cancer Chemother Pharmacol. 2015; 76: 75‒84
528）: Shiroiwa T, Takeuchi T, Fukuda T, et al: Cost-effectiveness of adjuvant FOLFOX therapy for stage Ⅲ colon cancer in Japan based on the MOSAIC trial. Value Health 2012; 15: 255‒260
529）: Yamanaka T, Oki E, Yamazaki K, et al: 12-Gene recurrence score assay stratifies the recurrence risk in stage Ⅱ/Ⅲ colon cancer with surgery alone: The SUNRISE study. J Clin Oncol 2016; 34: 2906‒2913
530）: Hong YS, Nam BH, Kim KP, et al: Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy（ADORE）: an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014; 15: 1245‒1253
531）: Kato T, Ohashi Y, Nakazato H, et al: Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbecks Arch Surg 2002; 386: 575‒581
532）: Akasu T, Moriya Y, Ohashi Y, et al: Adjuvant chemotherapy with uracil‒tegafur for pathological stage Ⅲ rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36: 237‒244
533）: Scheithauer W, Rosen H, Kornek GV, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752‒755
534）: O ’Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295‒300
535）: Chau I, Norman AR, Cunningham D, et al: A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549‒557
536）: Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091‒1097
537）: Sundararajan V, Mitra N, Jacobson JS, et al: Survival associated with 5-fluorouracil‒based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002; 136: 349‒357
538）: Jessup JM, Stewart A, Greene FL, et al: Adjuvant chemotherapy for stage Ⅲ colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703‒2711
539）: Sanoff HK, Carpenter WR, Stürmer T, et al: Effect of adjuvant chemotherapy on survival of patients with stage Ⅲ colon cancer diagnosed after age 75 years. J Clin Oncol 2012; 30: 2624‒2634
540）: McCleary NJ, Meyerhardt JA, Green E, et al: Impact of age on the efficacy of newer adjuvant therapies in patients with stage Ⅱ/Ⅲ colon cancer: findings from the ACCENT database. J Clin Oncol 2013; 31: 2600‒2606
541）: Haller DG, O’Connell MJ, Cartwright TH, et al: Impact of age and medical comorbidity on adjuvant treatment outcomes for stage Ⅲ colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol 2015; 26: 715‒724
542）: QUASAR Collaborative Group, Gray R, Barnwell J, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020‒2029
543）: Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage Ⅱ and Ⅲ colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797‒1806
544）: Figueredo A, Charette ML, Maroun J, et al: Adjuvant therapy for stage Ⅱ colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 2004; 22: 3395‒3407
545）: Schrag D, Rifas-Shiman S, Saltz L, et al: Adjuvant chemotherapy use for Medicare beneficiaries with stage Ⅱ colon cancer. J Clin Oncol 2002; 20: 3999‒4005
546）: Kajiwara Y, Ishiguro M, Teramukai S, et al: A randomized phase Ⅲ trial of 1-year adjuvant chemotherapy with oral tegafur‒uracil（UFT）vs. surgery alone in stage Ⅱ colon cancer: SACURA trial. J Clin Oncol 2016; 34: 3617
547）: Benson AB Ⅲ, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage Ⅱ colon cancer. J Clin Oncol 2004; 22: 3408‒3419
548）: Schmoll HJ, Van Cutsem E, Stein A, et al: ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479‒2516
549）: Grothey A, Sobrero AF, Shields AF, et al: Duration of adjuvant chemotherapy for stage Ⅲ colon cancer. N Engl J Med 2018; 378: 1177‒1188
550）: Iveson TJ, Kerr RS, Saunders MP, et al: 3 versus 6 months of adjuvant oxaliplatin‒fluoropyrimidine combination therapy for colorectal cancer（SCOT）: an international, randomised, phase 3, non-inferiority trial. Lancet Oncol 2018; 19: 562‒578
551）: Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219‒3226
552）: 石川敏昭，植竹宏之，石黒めぐみ，他: Stage Ⅱ結腸癌に対する術後補助化学療法の第Ⅲ相試験（SACURA trial）におけるMSI と予後の検討．第72 回日本消化器外科学会総会，2017，抄録O2‒82‒13‒1
553）: O ’Connell MJ, Lavery I, Yothers G, et al: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage Ⅱ/Ⅲ colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010; 28: 3937‒3944
554）: Gray RG, Quirke P, Handley K, et al: Validation study of a quantitative multigene reverse transcriptase‒polymerase chain reaction assay for assessment of recurrence risk in patients with stage Ⅱ colon cancer. J Clin Oncol 2011; 29: 4611‒4619
555）: Salazar R, Roepman P, Capella G, et al: Gene expression signature to improve prognosis prediction of stage Ⅱ and Ⅲ colorectal cancer. J Clin Oncol 2011; 29: 17‒24
556）: Kopetz S, Tabernero J, Rosenberg R, et al: Genomic classifier ColoPrint predicts recurrence in stage Ⅱ colorectal cancer patients more accurately than clinical factors. Oncologist 2015; 20: 127‒133
557）: Phallen J, Sausen M, Adleff V, et al: Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 2017; 9: pii: eaan2415
558）: Guinney J, Dienstmann R, Wang X, et al: The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350‒1356
559）: Dalerba P, Sahoo D, Paik S, et al: CDX2 as a prognostic biomarker in stage Ⅱ and stage Ⅲ colon cancer. N Engl J Med 2016; 374: 211‒222
560）: Lorenz M, Müller HH, Schramm H, et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases（Arbeitsgruppe Lebermetastasen）. Ann Surg 1998; 228: 756‒762
561）: 森　武生，高橋慶一，大植雅之，他: 大腸癌肝転移に対する肝切除後の残肝再発予防としての動注療法．消化器外科2001; 24: 313‒319
562）: Kemeny MM, Adak S, Gray B, et al: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy―an intergroup study. J Clin Oncol 2002; 20: 1499‒1505
563）: Portier G, Elias D, Bouche O, et al: Multicenter randomized trial of adjuvant fluorouracil and folnic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976‒4982
564）: Mitry E, Fields AL, Bleiberg H, et al: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906‒4911
565）: Okumura T, Boku N, Hishida T, et al: Surgical outcome and prognostic stratification for pulmonary metastasis from colorectal cancer. Ann Thorac Surg 2017; 104: 979‒987
566）: Sato H, Maeda K, Kotake K, et al: Factors affecting recurrence and prognosis after R0 resection for colorectal cancer with peritoneal metastasis. J Gastroenterol 2016; 51: 465‒472
567）: Kanemitsu Y, Kato T, Shimizu Y, et al: Colorectal Cancer Study Group（CCSG）of Japan Clinical Oncology Group: A randomized phase Ⅱ/Ⅲ trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol 2009; 39: 406‒409
568）: Cremolini C, Loupakis F, Masi G, et al: FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol 2016; 27: 843‒849
569）: Douillard JY, Oliner KS, Siena S, et al: Panitumumab‒FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023‒1034
570）: Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103‒2114
571）: Hecht JR, Cohn A, Dakhil S, et al: Randomized, multicenter, phase Ⅱ study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer 2015; 14: 72‒80
572）: Shitara K, Yonesaka K, Denda T, et al: A randomized multicenter phase Ⅱ study of FOLFIRI plus either panitumumab（Pmab）or bevacizumab（Bmab）as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer（mCRC）with exploratory biomarker analysis by liquid biopsy: WJOG6210G. 2016 ASCO Annual meeting; J Clin Oncol 34, 2016（suppl; abstr 3567）
573）: Bennouna J, Hiret S, Borg C, et al: Bevacizumab（Bev）or cetuximab（Cet）plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type（WT）KRAS metastatic colorectal cancer（mCRC）: Final analysis of a French randomized, multicenter, phase Ⅱ study（PRODIGE 18）. An Oncol 2017; 28: mdx393.004
574）: Wirapati P, Pomella V, Vandenbosch B, et al: LBA‒005VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. Ann Oncol 2017; 28（suppl_3）
575）: Yoshino T, Obermannova R, Bodoky G, et al: Are BRAF mutated metastatic colorectal cancer（mCRC）tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study―A global, randomized, double-blind, phase Ⅲ study. J Clin Oncol 2018; 36: no 4_suppl, 622
576）: Tabernero J, Hozak RR, Yoshino T, et al: Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase Ⅲ study. Ann Oncol 2018; 29: 602‒609
577）: Yoshino T, Komatsu Y, Yamada Y, et al: Randomized phase Ⅲ trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs 2015; 33: 740‒750
578）: Ohtsu A, Yoshino T, Wabha M, et al: RECOURSE Study Group. Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups. 2015 ASCO Annual Meeting; J Clin Oncol 33, 2015（suppl; abstr 3564）
579）: Li J, Qin S, Xu R, et al; CONCUR Investigators: Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer（CONCUR）: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16: 619‒629
580）: Abrahao ABK, Ko YJ, Berry S, et al: A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: A systematic review and network meta-analysis. Clin Colorectal Cancer 2018; 17: 113‒120
581）: Moriwaki T, Fukuoka S, Taniguchi H, et al: Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy（REGOTAS）: A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist 2018; 23: 7‒15
582）: Shitara K, Yamanaka T, Denda T, et al: REVERCE: A randomized phase Ⅱ study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol 2018 Dec 3［Epub ahead of print］
583）: Kuboki Y, Nishina T, Shinozaki E, et al: TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies（C‒TASK FORCE）: an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol 2017; 18: 1172‒1181
584）: Diaz LA, Marabelle A, Delord JP, et al: Pembrolizumab therapy for microsatellite instability high（MSI-H）colorectal cancer（CRC）and non-CRC［abstract］. J Clin Oncol 2017; 35 Suppl 3071
585）: Kemeny NE, Niedzwiecki D, Hollis DR, et al: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers（CALGB 9481）. J Clin Oncol 2006; 24: 1395‒1403
586）: Mocellin S, Pilati P, Lise M, et al: Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007; 25: 5649‒5654
587）: Kemeny N, Jarnagin W, Paty P, et al: Phase Ⅰ trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 4888‒4896
588）: Arai Y, Ohtsu A, Sato Y, et al: Phase Ⅰ/Ⅱ study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208‒DI. J Vasc Interv Radiol 2012; 23: 1261‒1267
589）: Nishiofuku H, Tanaka T, Aramaki T, et al: Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. Clin Colorectal Cancer 2010; 9: 305‒310
590）: Cercek A, Boucher TM, Gluskin JS, et al: Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J Surg Oncol 2016; 114: 655‒663
591）: Sauer R, Liersch T, Merkel S, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO‒94 randomized phase Ⅲ trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926‒1933
592）: Folkesson J, Birgisson H, Pahlman L, et al: Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644‒5650
593）: Birgisson H, Påhlman L, Gunnarsson U, et al: Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005; 23: 6126‒6131
594）: Kim JS, Kim JS, Cho MJ, et al: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54: 403‒408
595）: Rödel C, Grabenbauer GG, Papadopoulos T, et al: Phase Ⅰ/Ⅱ trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098‒3104
596）: Mohiuddin M, Winter K, Mitchell E, et al: Randomized phase Ⅱ study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24: 650‒655
597）: Cancer and Leukemia Group B 89901, Ryan DP, Niedzwiecki D, et al: Phase Ⅰ/Ⅱ study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006; 24: 2557‒2562
598）: Sato T, Kokuba Y, Koizumi W, et al: Phase Ⅰ trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 69: 1442‒1447
599）: Wong SJ, Winter K, Meropol NJ, et al: RTOG 0247: A randomized phase Ⅱ study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. Proc Am Soc Clin Oncol 2008; 26:（ Abstr 4021）
600）: Sato T, Ozawa H, Hatate K, et al: A Phase Ⅱ trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. Int J Radiat Oncol Biol Phys 2011; 79: 677‒683
601）: Spigel DR, Bendell JC, McCleod M, et al: Phase Ⅱ study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage Ⅱ/Ⅲ rectal cancer. Clin Colorectal Cancer 2012; 11: 45‒52
602）: Dewdney A, Cunningham D, Tabernero J, et al: Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer（EXPERT‒C）. J Clin Oncol 2012; 30: 1620‒1627
603）: Matsusaka S, Ishihara S, Kondo K, et al: A multicenter phase Ⅱ study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer（SHOGUN trial）. Radiother Oncol 2015; 116: 209‒213
604）: Noda M, Sato T, Hayakawa K, et al: A multicenter phase Ⅱ study of preoperative concurrent chemoradiotherapy with S-1 plus irinotecan for locally advanced rectal cancer: SAMRAI‒2. An Oncol 2016; 27: 477
605）: Renehan AG, Malcomson L, Emsley R, et al: Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer（the OnCoRe project）: a propensity-score matched cohort analysis. Lancet Oncol 2016; 17: 174‒183
606）: Rullier E, Rouanet P, Tuech JJ, et al: Organ preservation for rectal cancer（GRECCAR 2）: a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet 2017; 390: 469‒479
607）: Schrag D, Weiser MR, Goodman KA, et al: Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014; 32: 513‒518
608）: Kamiya T, Uehara K, Nakayama G, et al; Nagoya Surgical Oncology Group and the Chubu Clinical Oncology Group: Early results of multicenter phase Ⅱ trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA Ⅰ study. Eur J Surg Oncol 2016; 42: 829‒835
609）: Glynne-Jones R, Hava N, Goh V, et al; Bacchus investigators: Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery（BACCHUS）: a phase Ⅱ, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer 2015; 15: 764
610）: Deng Y, Chi P, Lan P, et al: Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase Ⅲ Trial. J Clin Oncol 2016; 34: 3300‒3307
611）: De Paoli A, Chiara S, Luppi G, et al: Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase Ⅱ study. Ann Oncol 2006; 17: 246‒251
612）: Aschele C, Friso ML, Pucciarelli S, et al: A phase Ⅰ‒Ⅱ study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 2005; 16: 1140‒1146
613）: Mehta VK, Cho C, Ford JM, et al: Phase Ⅱ trial of preoperative 3 D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003; 55: 132‒137
614）: Braendengen M, Tveit KM, Berglund A, et al: Randomized phase Ⅲ study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26: 3687‒3694
615）: Bujko K, Nasierowska-Guttmejer A, Wyrwicz L, et al; Polish Colorectal Study Group: Neoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized study. Radiother Oncol 2013; 107: 171‒177
616）: Engineer R, Mohandas KM, Shukla PJ, et al: Escalated radiation dose alone vs. concurrent chemoradiation for locally advanced and unresectable rectal cancers: results from phase Ⅱ randomized study. Int J Colorectal Dis 2013; 28: 959‒966
617）: Vestermark LW, Jensen HA, Pfeiffer P: High-dose radiotherapy（60 Gy）with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer（LARC）: a Phase Ⅰ trial. Acta Oncol 2012; 51: 311‒317
618）: Das P, Delclos ME, Skibber JM, et al: Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys 2010; 77: 60‒65
619）: Sun DS, Zhang JD, Li L, et al: Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. Br J Radiol 2012; 85: 259‒264
620）: Freedman GM, Meropol NJ, Sigurdson ER, et al: Phase Ⅰ trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67: 1389‒1393
621）: van Hooft JE, van Halsema EE, Vanbiervliet G, et al; European Society of Gastrointestinal Endoscopy（ESGE）:Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy（ESGE）Clinical Guideline. Gastrointest Endosc 2014; 80: 747‒761. e1‒75
622）: Zhao XD, Cai BB, Cao RS, et al: Palliative treatment for incurable malignant colorectal obstructions: a meta-analysis. World J Gastroenterol 2013; 19: 5565‒5574
623）: 厚生労働省医薬食品局: 消化管用ステントに係る使用上の注意の改訂について．薬食安発1107 第1 号，薬食機発 1107 第1 号，平成24 年11 月7 日　http://www.pmda.go.jp/files/000148167.pdf
624）: Huang X, Lv B, Zhang S, et al: Preoperative colonic stents versus emergency surgery for acute left-sided malignant colonic obstruction: a meta-analysis. J Gastrointest Surg 2014; 18: 584‒591
625）: Cirocchi R, Farinella E, Trastulli S, et al: Safety and efficacy of endoscopic colonic stenting as a bridge to surgery in the management of intestinal obstruction due to left colon and rectal cancer: a systematic review and metaanalysis. Surg Oncol 2013; 22: 14‒21
626）: Cennamo V, Luigiano C, Coccolini F, et al: Meta-analysis of randomized trials comparing endoscopic stenting and surgical decompression for colorectal cancer obstruction. Int J Colorectal Dis 2013; 28: 855‒863
627）: Zhang Y, Shi J, Shi B, et al: Self-expanding metallic stent as a bridge to surgery versus emergency surgery for obstructive colorectal cancer: a meta-analysis. Surg Endosc 2012; 26: 110‒119
628）: Gorissen KJ, Tuynman JB, Fryer E, et al: Local recurrence after stenting for obstructing left-sided colonic cancer. Br J Surg 2013; 100: 1805‒1809
629）: Sabbagh C, Browet F, Diouf M, et al: Is stenting as“a bridge to surgery”an oncologically safe strategy for the management of acute, left-sided, malignant, colonic obstruction? A comparative study with a propensity score analysis. Ann Surg 2013; 258: 107‒115
630）: Choi JM, Lee C, Han YM, et al: Long-term oncologic outcomes of endoscopic stenting as a bridge to surgery for malignant colonic obstruction: comparison with emergency surgery. Surg Endosc 2014; 28: 2649‒2655
631）: Matsuda A, Miyashita M, Matsumoto S, et al: Comparison of long-term outcomes of colonic stent as “bridge to surgery” and emergency surgery for malignant large-bowel obstruction: a meta-analysis. Ann Surg Oncol 2015; 22: 497‒504
632）: 大腸ステント安全手技研究会: 大腸ステント安全留置のためのミニガイドライン．大腸ステント安全留置のポイント（2017.10.16 改訂）．https://colon-stent.com/doc/Document05.pdf
633）: Kuwai T, Kyo R, Yoshida S, et al: A prospective, multicenter study of palliative colonic stenting for malignant colorectal obstruction in Japan: long-term efficacy and safety in 87 patients. Gastrointest Endosc 2017; 85: suppl, AB254（DDW2017, SA1719）
634）: Saito S, Yoshida S, Isayama H, et al: A prospective multicenter study on self-expandable metallic stents as a bridge to surgery for malignant colorectal obstruction in Japan: efficacy and safety in 312 patients. Surg Endosc 2016; 30: 3976‒3986
635）: Rex DK, Kahi CJ, Levin B, et al; American Cancer Society; US Multi-Society Task Force on Colorectal Cancer: Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006; 130: 1865‒1871
636）: Mulder SA, Kranse R, Damhuis RA, et al: The incidence and risk factors of metachronous colorectal cancer: an indication for follow-up. Dis Colon Rectum 2012; 55: 522‒531
637）: Levi F, Randimbison L, Blanc-Moya R, et al: High constant incidence of second primary colorectal cancer. Int J Cancer 2013; 132: 1679‒1682
638）: Dasgupta P, Youlden DR, Baade PD: Multiple primary cancers among colorectal cancer survivors in Queensland, Australia, 1996‒2007. Cancer Causes Control 2012; 23: 1387‒1398
639）: National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology‒colon cancer, version 2, 2017. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf（accessed 14 December 2017）
640）: Chen TA, Horng JT, Lin WC: Metachronous colorectal cancer in Taiwan: analyzing 20 years of data from Taiwan Cancer Registry. Int J Clin Oncol 2013; 18: 267‒272
641）: Sakamoto T, Matsuda T, Nakajima T, et al: How often should we perform surveillance colonoscopy after surgery for colorectal cancer? Int J Colorectal Dis 2013; 28: 835‒840
642）: Gan S, Wilson K, Hollington P: Surveillance of patients following surgery with curative intent for colorectal cancer. World J Gastroenterol 2007; 13: 3816‒3823. Review
643）: Arditi C, Gonvers JJ, Burnand B, et al; EPAGE Ⅱ Study Group: Appropriateness of colonoscopy in Europe（EPAGE Ⅱ）. Surveillance after polypectomy and after resection of colorectal cancer. Endoscopy 2009; 41: 209‒217
644）: 甲斐俊吉，小泉浩一，今里　真，他: 大腸癌切除後の異時性重複癌について―大腸と他臓器との重複癌の検討―．外科1995; 57: 1300‒1305
645）: 万井真理子，吉川宣輝，西庄　勇，他: 大腸重複癌の臨床病理学的検討．日本大腸肛門病会誌2000; 53: 540‒546
646）: 塩澤　学，土田知史，菅野伸洋，他: 大腸癌における多臓器重複癌の検討．日消外会誌2007; 40: 1557‒1564
647）: Tanaka H, Hiyama T, Hanai A, et al: Second primary cancers following colon and rectal cancer in Osaka, Japan. Jpn J Cancer Res 1991; 82: 1356‒1365
648）: 寺本龍生，渡邊昌彦，北島政樹: 大腸癌二次発癌のサーベイランスと対策．消化器癌1997; 7: 169‒172
649）: Tsukuma H, Fujimoto I, Hanai A, et al: Incidence of second primary cancers in Osaka residents, Japan, with special reference to cumulative and relative risks. Jpn J Cancer Res 1994; 85: 339‒345
650）: Ueno M, Muto T, Oya M, et al: Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol 2003; 8: 162‒167
651）: Noura S, Ohue M, Seki Y, et al: Second primary cancer in patients with colorectal cancer after a curative resection. Dig Surg 2009; 26: 400‒405
652）: Yamamoto S, Yoshimura K, Ri S, et al: The risk of multiple primary malignancies with colorectal carcinoma. Dis Colon Rectum 2006; 49: S30‒S36
653）: Hoar SK, Wilson J, Blot WJ, et al: Second cancer following cancer of the digestive system in Connecticut, 1935‒82. Natl Cancer Inst Monogr 1985; 68: 49‒82
654）: McCredie M, Macfarlane GJ, Bell J, et al: Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972‒1991. Cancer Epidemiol Biomarkers Prev 1997; 6: 155‒160
655）: Armed F, Goodman MT, Kosary C, et al: Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975‒2001. Cancer 2006; 107: 1162‒1171
656）: Lynge E, Jensen OM, Carstensen B: Second cancer following cancer of the digestive system in Denmark, 1943‒80. Natl Cancer Inst Monogr 1985; 68: 277‒308
657）: Buiatti E, Crocetti E, Acciai A, et al: Incidence of second primary cancers in three Italian population-based cancer registries. Eur J Cancer 1997; 33: 1829‒1834
658）: Evans HS, Møller H, Robinson D, et al: The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut 2002; 50: 647‒652
659）: 島谷英彦，藤井久男，小山文一，他: 大腸他臓器重複癌症例の検討．日本大腸肛門病会誌2003; 56: 294‒298